NLRP1NACHT, LRR and PYD domains-containing protein 1
Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis.
UniProt locations Cytoplasm, cytosol · Cytoplasm · Nucleus · Inflammasome
Function
Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis [12, 18, 10, 47, 49, 50, 35, 37, 42, 39]. Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation [12, 18, 10]. Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as cleavage by some human enteroviruses and rhinoviruses, double-stranded RNA, UV-B irradiation, or Val-boroPro inhibitor, and mediates the formation of the inflammasome polymeric complex composed of NLRP1, CASP1 and PYCARD/ASC [12, 18, 10, 27, 30, 29, 50, 33, 35, 39].
In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and associates with PYCARD/ASC to initiate the formation of the inflammasome complex: the NLRP1 inflammasome recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis [12, 18, 10, 32, 50]. In the absence of GSDMD expression, the NLRP1 inflammasome is able to recruit and activate CASP8, leading to activation of gasdermin-E (GSDME) [34, 36]. Activation of NLRP1 inflammasome is also required for HMGB1 secretion; the active cytokines and HMGB1 stimulate inflammatory responses [23].
Binds ATP and shows ATPase activity [4, 14, 33]. Plays an important role in antiviral immunity and inflammation in the human airway epithelium [50]. Specifically recognizes a number of pathogen-associated signals: upon infection by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), NLRP1 is cleaved and activated which triggers NLRP1-dependent inflammasome activation and IL18 secretion [50].
Positive-strand RNA viruses, such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome, triggering IL1B release in a NLRP1-dependent fashion [33]. Acts as a direct sensor for long dsRNA and thus RNA virus infection [33]. May also be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner [19].
The NLRP1 inflammasome is also activated in response to UV-B irradiation causing ribosome collisions: ribosome collisions cause phosphorylation and activation of NLRP1 in a MAP3K20-dependent manner, leading to pyroptosis [39]
Evidence & references
- ECO:0000269 PubMed:11113115 ↗
- ECO:0000269 PubMed:12191486 ↗
- ECO:0000269 PubMed:15212762 ↗
- ECO:0000269 PubMed:17349957 ↗
- ECO:0000269 PubMed:18511561 ↗
- ECO:0000269 PubMed:22665479 ↗
- ECO:0000269 PubMed:22801494 ↗
- ECO:0000269 PubMed:25562666 ↗
- ECO:0000269 PubMed:27662089 ↗
- ECO:0000269 PubMed:30096351 ↗
- ECO:0000269 PubMed:30291141 ↗
- ECO:0000269 PubMed:31484767 ↗
- ECO:0000269 PubMed:32051255 ↗
- ECO:0000269 PubMed:33093214 ↗
- ECO:0000269 PubMed:33243852 ↗
- ECO:0000269 PubMed:33410748 ↗
- ECO:0000269 PubMed:33731929 ↗
- ECO:0000269 PubMed:33731932 ↗
- ECO:0000269 PubMed:33852854 ↗
- ECO:0000269 PubMed:35594856 ↗
- ECO:0000269 PubMed:35857590 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11113115"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12191486"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15212762"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17349957"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18511561"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22801494"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "25562666"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27662089"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "30096351"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "30291141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "31484767"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "32051255"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33410748"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731929"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731932"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33852854"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35594856"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35857590"
}
],
"value": "Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:27662089, PubMed:31484767, PubMed:33093214, PubMed:33410748, PubMed:33731929, PubMed:33731932, PubMed:35857590). Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation (PubMed:12191486, PubMed:17349957, PubMed:22665479). Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as cleavage by some human enteroviruses and rhinoviruses, double-stranded RNA, UV-B irradiation, or Val-boroPro inhibitor, and mediates the formation of the inflammasome polymeric complex composed of NLRP1, CASP1 and PYCARD/ASC (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:25562666, PubMed:30096351, PubMed:30291141, PubMed:33093214, PubMed:33243852, PubMed:33410748, PubMed:35857590). In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and associates with PYCARD/ASC to initiate the formation of the inflammasome complex: the NLRP1 inflammasome recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:32051255, PubMed:33093214). In the absence of GSDMD expression, the NLRP1 inflammasome is able to recruit and activate CASP8, leading to activation of gasdermin-E (GSDME) (PubMed:33852854, PubMed:35594856). Activation of NLRP1 inflammasome is also required for HMGB1 secretion; the active cytokines and HMGB1 stimulate inflammatory responses (PubMed:22801494). Binds ATP and shows ATPase activity (PubMed:11113115, PubMed:15212762, PubMed:33243852). Plays an important role in antiviral immunity and inflammation in the human airway epithelium (PubMed:33093214). Specifically recognizes a number of pathogen-associated signals: upon infection by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), NLRP1 is cleaved and activated which triggers NLRP1-dependent inflammasome activation and IL18 secretion (PubMed:33093214). Positive-strand RNA viruses, such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome, triggering IL1B release in a NLRP1-dependent fashion (PubMed:33243852). Acts as a direct sensor for long dsRNA and thus RNA virus infection (PubMed:33243852). May also be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner (PubMed:18511561). The NLRP1 inflammasome is also activated in response to UV-B irradiation causing ribosome collisions: ribosome collisions cause phosphorylation and activation of NLRP1 in a MAP3K20-dependent manner, leading to pyroptosis (PubMed:35857590)"
}
],
"commentType": "FUNCTION"
}Constitutes the precursor of the NLRP1 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals
Evidence & references
- ECO:0000269 PubMed:22087307 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22087307"
}
],
"value": "Constitutes the precursor of the NLRP1 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals"
}
],
"commentType": "FUNCTION",
"molecule": "NACHT, LRR and PYD domains-containing protein 1"
}Regulatory part that prevents formation of the NLRP1 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus), preventing activation of the NLRP1 inflammasome [50]. In response to pathogen-associated signals, this part is ubiquitinated and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the NLRP1 inflammasome [50]
Evidence & references
- ECO:0000269 PubMed:33093214 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
}
],
"value": "Regulatory part that prevents formation of the NLRP1 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214). In response to pathogen-associated signals, this part is ubiquitinated and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the NLRP1 inflammasome (PubMed:33093214)"
}
],
"commentType": "FUNCTION",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}Constitutes the active part of the NLRP1 inflammasome [50, 37, 42]. In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus), preventing activation of the NLRP1 inflammasome [50]. In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing this form, which polymerizes and associates with PYCARD/ASC to form of the NLRP1 inflammasome complex: the NLRP1 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis [50]
Evidence & references
- ECO:0000269 PubMed:33093214 ↗
- ECO:0000269 PubMed:33731929 ↗
- ECO:0000269 PubMed:33731932 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731929"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731932"
}
],
"value": "Constitutes the active part of the NLRP1 inflammasome (PubMed:33093214, PubMed:33731929, PubMed:33731932). In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214). In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing this form, which polymerizes and associates with PYCARD/ASC to form of the NLRP1 inflammasome complex: the NLRP1 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis (PubMed:33093214)"
}
],
"commentType": "FUNCTION",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}It is unclear whether is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release [10]. However, in an vitro cell-free system, it has been shown to be activated by MDP [18]
Evidence & references
- ECO:0000269 PubMed:17349957 ↗
- ECO:0000269 PubMed:22665479 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17349957"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
}
],
"value": "It is unclear whether is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release (PubMed:22665479). However, in an vitro cell-free system, it has been shown to be activated by MDP (PubMed:17349957)"
}
],
"commentType": "FUNCTION",
"molecule": "Isoform 2"
}Additional functional context
In macrophages and dendritic cells, NLRP1 inflammasome activation of CASP1 and IL1B maturation can be dampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, such as CD40LG
Evidence & references
- ECO:0000250 UniProtKB:Q2LKW6
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "Q2LKW6"
}
],
"value": "In macrophages and dendritic cells, NLRP1 inflammasome activation of CASP1 and IL1B maturation can be dampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, such as CD40LG"
}
],
"commentType": "MISCELLANEOUS"
}Catalytic activity
ATP + H2O = ADP + phosphate + H(+)
Evidence
- ECO:0000269 PubMed:33243852 ↗
Complete source annotation
{
"commentType": "CATALYTIC ACTIVITY",
"reaction": {
"name": "ATP + H2O = ADP + phosphate + H(+)",
"reactionCrossReferences": [
{
"database": "Rhea",
"id": "RHEA:13065"
},
{
"database": "ChEBI",
"id": "CHEBI:15377"
},
{
"database": "ChEBI",
"id": "CHEBI:15378"
},
{
"database": "ChEBI",
"id": "CHEBI:30616"
},
{
"database": "ChEBI",
"id": "CHEBI:43474"
},
{
"database": "ChEBI",
"id": "CHEBI:456216"
}
],
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
]
},
"physiologicalReactions": [
{
"directionType": "left-to-right",
"reactionCrossReference": {
"database": "Rhea",
"id": "RHEA:13066"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
]
}
]
}Activity regulation
NLRP1 inflammasome is activated by cleavage by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16): cleavage promotes ubiquitination and degradation of the N-terminal part, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome [50, 35]. Activated double-stranded RNA: positive-strand RNA viruses such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome [33]. In contrast to its mouse ortholog, not activated by Bacillus anthracis lethal toxin [21].
NLRP1 inflammasome is inhibited by DPP8 and DPP9, which sequester the C-terminal fragment of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in a ternary complex, thereby preventing NLRP1 oligomerization and activation [29, 31, 37, 42]. NLRP1 inflammasome is activated by Val-boroPro (Talabostat, PT-100), an inhibitor of dipeptidyl peptidases DPP8 and DPP9 [29, 37, 42]. Val-boroPro relieves inhibition of DPP8 and/or DPP9 by promoting disruption of the ternary complex, releasing its C-terminal part from autoinhibition [37, 42].
ATPase activity is activated by dsRNA-binding but not dsDNA-binding [33]
Evidence & references
- ECO:0000269 PubMed:19651869 ↗
- ECO:0000269 PubMed:30291141 ↗
- ECO:0000269 PubMed:31525884 ↗
- ECO:0000269 PubMed:33093214 ↗
- ECO:0000269 PubMed:33243852 ↗
- ECO:0000269 PubMed:33410748 ↗
- ECO:0000269 PubMed:33731929 ↗
- ECO:0000269 PubMed:33731932 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19651869"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "30291141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "31525884"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33410748"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731929"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731932"
}
],
"value": "NLRP1 inflammasome is activated by cleavage by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16): cleavage promotes ubiquitination and degradation of the N-terminal part, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome (PubMed:33093214, PubMed:33410748). Activated double-stranded RNA: positive-strand RNA viruses such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome (PubMed:33243852). In contrast to its mouse ortholog, not activated by Bacillus anthracis lethal toxin (PubMed:19651869). NLRP1 inflammasome is inhibited by DPP8 and DPP9, which sequester the C-terminal fragment of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in a ternary complex, thereby preventing NLRP1 oligomerization and activation (PubMed:30291141, PubMed:31525884, PubMed:33731929, PubMed:33731932). NLRP1 inflammasome is activated by Val-boroPro (Talabostat, PT-100), an inhibitor of dipeptidyl peptidases DPP8 and DPP9 (PubMed:30291141, PubMed:33731929, PubMed:33731932). Val-boroPro relieves inhibition of DPP8 and/or DPP9 by promoting disruption of the ternary complex, releasing its C-terminal part from autoinhibition (PubMed:33731929, PubMed:33731932). ATPase activity is activated by dsRNA-binding but not dsDNA-binding (PubMed:33243852)"
}
],
"commentType": "ACTIVITY REGULATION"
}(Microbial infection) The NLRP1 inflammasome is activated by human herpes virus 8/HHV-8 protein ORF45, which interacts with the N-terminal part of NLRP1 and promotes its translocation into the nucleus, relieving autoinhibition and leading to activation
Evidence & references
- ECO:0000269 PubMed:35618833 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35618833"
}
],
"value": "(Microbial infection) The NLRP1 inflammasome is activated by human herpes virus 8/HHV-8 protein ORF45, which interacts with the N-terminal part of NLRP1 and promotes its translocation into the nucleus, relieving autoinhibition and leading to activation"
}
],
"commentType": "ACTIVITY REGULATION"
}(Microbial infection) NLRP1 inflammasome is activated by cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2
Evidence & references
- ECO:0000269 PubMed:35594856 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35594856"
}
],
"value": "(Microbial infection) NLRP1 inflammasome is activated by cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2"
}
],
"commentType": "ACTIVITY REGULATION"
}GO functions & biological processes
GO:0003690 · evidence & context
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207qualifier: enables
GO:0003725 · evidence & context
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207qualifier: enables
GO:0005515 · evidence & context
- ECO:0000353 PMID:11472070 ↗ IPI · UniProt · 20061120qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPP4"}]}]
- ECO:0000353 PMID:15107016 ↗ IPI · HGNC-UCL · 20060524qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
- ECO:0000353 PMID:15107016 ↗ IPI · HGNC-UCL · 20060524qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPP4"}]}]
- ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10415"}]}]
- ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
- ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07817"}]}]
- ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}]
- ECO:0000353 PMID:18511561 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
- ECO:0000353 PMID:19223583 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10415"}]}]
- ECO:0000353 PMID:19223583 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07817-1"}]}]
- ECO:0000353 PMID:19337385 ↗ IPI · BHF-UCL · 20110124qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9HC29"}]}]
- ECO:0000353 PMID:22801494 ↗ IPI · UniProt · 20130416qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P19525"}]}]
- ECO:0000353 PMID:30291141 ↗ IPI · UniProt · 20210503qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86TI2"}]}]
- ECO:0000353 PMID:33731929 ↗ IPI · UniProt · 20211222qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86TI2"}]}]
GO:0005524 · evidence & context
- ECO:0000314 PMID:15212762 ↗ IDA · HGNC-UCL · 20060524qualifier: enables
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207qualifier: enables
GO:0008656 · evidence & context
- ECO:0000303 PMID:11076957 ↗ NAS · UniProt · 20020906qualifier: enables
All recorded function and process assertions (40)
GO:0016887 · evidence & context
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20210316qualifier: enables
GO:0019899 · evidence & context
- ECO:0000353 PMID:11076957 ↗ IPI · UniProt · 20021104qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P42575"}]}]
GO:0019904 · evidence & context
- ECO:0000353 PMID:16575408 ↗ IPI · UniProt · 20090511qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95361"}]}]
GO:0035591 · evidence & context
- ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220125qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q9ULZ3", "relation": "has_input"}, {"db": "GO", "id": "0140608", "relation": "directly_positively_regulates"}]}]
GO:0038187 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
GO:0038187 · evidence & context
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20220125qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
GO:0140608 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
- ECO:0000314 PMID:30291141 ↗ IDA · UniProt · 20210504qualifier: enables
GO:0140608 · evidence & context
- ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220811qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "GO", "id": "0005829", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "P29466", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
GO:0140608 · evidence & context
- ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220916qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "P29466", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
GO:0140608 · evidence & context
- ECO:0000314 PMID:33852854 ↗ IDA · UniProt · 20220916qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}]}]
- ECO:0000314 PMID:35594856 ↗ IDA · UniProt · 20220916qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}]}]
GO:0140608 · evidence & context
- ECO:0000314 PMID:33852854 ↗ IDA · UniProt · 20220916qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
GO:0140693 · evidence & context
- ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20220125qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
- ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20220125qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
GO:0140693 · evidence & context
- ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20220916qualifier: enablesextensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "GO", "id": "0035591", "relation": "directly_positively_regulates"}]}]
GO:0002218 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250413qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
GO:0002221 · evidence & context
- ECO:0005547 PMID:22258606 ↗ NAS · ComplexPortal · 20250804qualifier: involved_in
GO:0006915 · evidence & context
- ECO:0000303 PMID:11076957 ↗ NAS · UniProt · 20020906qualifier: involved_in
GO:0006954 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR033516"}]}]
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20241121qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:3582959"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
GO:0007165 · evidence & context
- ECO:0000315 PMID:30096351 ↗ IMP · UniProt · 20240117qualifier: involved_in
GO:0032495 · evidence & context
- ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
GO:0032731 · evidence & context
- ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00033916"}]}]
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207qualifier: involved_in
- ECO:0000314 PMID:7642516 ↗ IDA · ComplexPortal · 20250804qualifier: involved_in
GO:0042742 · evidence & context
- ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
GO:0042981 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001315"}]}]
GO:0045087 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR033516"}]}]
GO:0050727 · evidence & context
- ECO:0000314 PMID:15212762 ↗ IDA · BHF-UCL · 20240215qualifier: involved_in
GO:0050729 · evidence & context
- ECO:0000314 PMID:12191486 ↗ IDA · ComplexPortal · 20250804qualifier: involved_in
GO:0051260 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089314"}]}]
- ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20210504qualifier: involved_in
- ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20210504qualifier: involved_in
GO:0051402 · evidence & context
- ECO:0000314 PMID:15212762 ↗ IDA · HGNC-UCL · 20060524qualifier: involved_in
GO:0051607 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00026923"}]}]
- ECO:0000314 PMID:33093214 ↗ IDA · UniProt · 20201030qualifier: involved_in
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207qualifier: involved_in
GO:0070269 · evidence & context
- ECO:0005547 PMID:26611636 ↗ NAS · ComplexPortal · 20250804qualifier: involved_in
- ECO:0000314 PMID:33093214 ↗ IDA · UniProt · 20201030qualifier: involved_in
GO:0071493 · evidence & context
- ECO:0000315 PMID:30096351 ↗ IMP · UniProt · 20220810qualifier: involved_in
GO:0097193 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}]
GO:0097264 · evidence & context
- ECO:0000314 PMID:33093214 ↗ IDA · UniProt · 20201030qualifier: involved_in
GO:0140374 · evidence & context
- ECO:0000314 PMID:33093214 ↗ IDA · UniProt · 20201030qualifier: involved_in
GO:0140632 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00085691"}]}]
GO:1904784 · evidence & context
- ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220916qualifier: involved_in
- ECO:0000315 PMID:27662089 ↗ IMP · UniProt · 20170517qualifier: involved_in
- ECO:0000315 PMID:31484767 ↗ IMP · UniProt · 20200807qualifier: involved_in
- ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20220125qualifier: involved_in
- ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20220125qualifier: involved_in
- ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20220916qualifier: involved_in
- ECO:0000314 PMID:33852854 ↗ IDA · UniProt · 20220916qualifier: involved_in
- ECO:0000314 PMID:35594856 ↗ IDA · UniProt · 20220916qualifier: involved_in
Names & Taxonomy
- Recommended name
- NACHT, LRR and PYD domains-containing protein 1
- Gene
- NLRP1
- Accession / entry
- Q9C000 · NLRP1_HUMAN
- Species
- Homo sapiens · NCBI 9606
- Recorded aliases
- CARD7 · Caspase recruitment domain-containing protein 7 · DEFCAP · Death effector filament-forming ced-4-like apoptosis protein · KIAA0926 · NAC · NALP1 · Nucleotide-binding domain and caspase recruitment domain
Full taxonomy & recorded names
Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo
{
"names": {
"recommendedName": {
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "NACHT, LRR and PYD domains-containing protein 1"
},
"ecNumbers": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22087307"
}
],
"value": "3.4.-.-"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
],
"value": "3.6.4.-"
}
]
},
"alternativeNames": [
{
"fullName": {
"value": "Caspase recruitment domain-containing protein 7"
}
},
{
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11076957"
}
],
"value": "Death effector filament-forming ced-4-like apoptosis protein"
}
},
{
"fullName": {
"value": "Nucleotide-binding domain and caspase recruitment domain"
}
}
],
"contains": [
{
"recommendedName": {
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
},
"shortNames": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "33420033"
}
],
"value": "NLRP1-CT"
}
]
}
},
{
"recommendedName": {
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
},
"shortNames": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "33420033"
}
],
"value": "NLRP1-NT"
}
]
}
}
]
},
"genes": [
{
"geneName": {
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "22665479"
},
{
"evidenceCode": "ECO:0000312",
"source": "HGNC",
"id": "HGNC:14374"
}
],
"value": "NLRP1"
},
"synonyms": [
{
"value": "CARD7"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11076957"
}
],
"value": "DEFCAP"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "10231032"
}
],
"value": "KIAA0926"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11113115"
}
],
"value": "NAC"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "15285719"
}
],
"value": "NALP1"
}
]
}
]
}Subcellular Location
UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.
Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic
Evidence & references
- ECO:0000269 PubMed:17418785 ↗
Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic
Evidence & references
- ECO:0000269 PubMed:17164409 ↗
Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic
Evidence & references
- ECO:0000269 PubMed:17164409 ↗
NACHT, LRR and PYD domains-containing protein 1, C-terminus
Evidence & references
- ECO:0000269 PubMed:12191486 ↗
- ECO:0000269 PubMed:22665479 ↗
- ECO:0000269 PubMed:30291141 ↗
- ECO:0000269 PubMed:33420028 ↗
- ECO:0000269 PubMed:33420033 ↗
NACHT, LRR and PYD domains-containing protein 1, N-terminus
(Microbial infection) Interaction with human herpes virus 8/HHV-8 proteins ORF45 promotes translocation of the N-terminal part of NLRP1 into the nucleus, relieving autoinhibition of the NLRP1 inflammasome and leading to its activation
Evidence & references
- ECO:0000269 PubMed:35618833 ↗
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260530qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
Evidence & references
- ECO:0000314 PMID:17164409 ↗ IDA · UniProt · 20220125qualifier: is_active_in
- ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220811qualifier: is_active_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
- ECO:0000314 PMID:17164409 ↗ IDA · BHF-UCL · 20110124qualifier: located_in
- ECO:0000269 PMID:35618833 ↗ EXP · UniProt · 20250406qualifier: located_in
All recorded location assertions (15)
Evidence & references
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
Evidence & references
- ECO:0005547 PMID:28263976 ↗ NAS · ComplexPortal · 20250804qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0086"}]}]
- ECO:0000269 PMID:17164409 ↗ EXP · UniProt · 20250406qualifier: located_in
- ECO:0005547 PMID:28263976 ↗ NAS · ComplexPortal · 20250804qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0091"}]}]
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000304 Reactome:R-HSA-844438 TAS · Reactome · 20130516qualifier: located_in
- ECO:0000304 Reactome:R-HSA-844447 TAS · Reactome · 20130516qualifier: located_in
- ECO:0000304 Reactome:R-HSA-879201 TAS · Reactome · 20130516qualifier: located_in
- ECO:0000304 Reactome:R-HSA-879222 TAS · Reactome · 20130516qualifier: located_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: part_ofwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0488"}]}]
- ECO:0000269 PMID:12191486 ↗ EXP · UniProt · 20250406qualifier: part_of
- ECO:0000269 PMID:22665479 ↗ EXP · UniProt · 20250406qualifier: part_of
- ECO:0000269 PMID:30291141 ↗ EXP · UniProt · 20250406qualifier: part_of
- ECO:0000269 PMID:33420028 ↗ EXP · UniProt · 20250406qualifier: part_of
- ECO:0000269 PMID:33420033 ↗ EXP · UniProt · 20250406qualifier: part_of
Evidence & references
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: part_ofwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00092910"}]}]
- ECO:0000314 PMID:12191486 ↗ IDA · UniProt · 20121018qualifier: part_of
- ECO:0000353 PMID:17349957 ↗ IPI · ComplexPortal · 20250804qualifier: part_of
- ECO:0000304 PMID:20303873 ↗ TAS · BHF-UCL · 20110223qualifier: part_of
- ECO:0000314 PMID:30291141 ↗ IDA · UniProt · 20210504qualifier: part_of
- ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20210504qualifier: part_of
- ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20210504qualifier: part_of
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411qualifier: part_ofwithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-000511-2"}]}]
Membrane topology 0
No annotation is recorded in this UniProt entry.
Disease & Variants
Source annotations; a recorded variant is not automatically a clinical classification.
Vitiligo-associated multiple autoimmune disease 1 VAMAS1
A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
Evidence & references
- ECO:0000269 PubMed:17377159 ↗
Disease susceptibility is associated with variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Vitiligo-associated multiple autoimmune disease 1",
"diseaseAccession": "DI-02736",
"acronym": "VAMAS1",
"description": "A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.",
"diseaseCrossReference": {
"database": "MIM",
"id": "606579"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17377159"
}
]
},
"note": {
"texts": [
{
"value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
}
]
}
}Palmoplantar carcinoma, multiple self-healing MSPC
An autosomal dominant disease characterized by keratopathy with neovascularization, bilateral corneal opacification, palmoplantar hyperkeratosis, dyshidrosis, dystrophic nails, and recurrent keratoacanthomas in palmoplantar skin as well as in conjunctival and corneal epithelia. In addition, patients experience a high susceptibility to malignant squamous cell carcinoma.
Evidence & references
- ECO:0000269 PubMed:23349227 ↗
- ECO:0000269 PubMed:27662089 ↗
- ECO:0000269 PubMed:33093214 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Palmoplantar carcinoma, multiple self-healing",
"diseaseAccession": "DI-03762",
"acronym": "MSPC",
"description": "An autosomal dominant disease characterized by keratopathy with neovascularization, bilateral corneal opacification, palmoplantar hyperkeratosis, dyshidrosis, dystrophic nails, and recurrent keratoacanthomas in palmoplantar skin as well as in conjunctival and corneal epithelia. In addition, patients experience a high susceptibility to malignant squamous cell carcinoma.",
"diseaseCrossReference": {
"database": "MIM",
"id": "615225"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23349227"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27662089"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Autoinflammation with arthritis and dyskeratosis AIADK
A disorder characterized by recurrent fever, diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Inheritance can be autosomal dominant or autosomal recessive.
Evidence & references
- ECO:0000269 PubMed:27965258 ↗
- ECO:0000269 PubMed:30291141 ↗
- ECO:0000269 PubMed:33731932 ↗
The disease may be caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Autoinflammation with arthritis and dyskeratosis",
"diseaseAccession": "DI-04967",
"acronym": "AIADK",
"description": "A disorder characterized by recurrent fever, diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Inheritance can be autosomal dominant or autosomal recessive.",
"diseaseCrossReference": {
"database": "MIM",
"id": "617388"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27965258"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "30291141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731932"
}
]
},
"note": {
"texts": [
{
"value": "The disease may be caused by variants affecting the gene represented in this entry"
}
]
}
}Respiratory papillomatosis, juvenile recurrent, congenital JRRP
An autosomal recessive disease characterized by recurrent growth of papillomas in the respiratory tract, and onset in early childhood. Papillomas are most commonly found in the larynx but may occur anywhere from the mouth to the bronchi. Children typically present within the first years of life with hoarseness or, in more severe cases, respiratory distress or stridor and airway obstruction. JRRP is associated with infection of the upper airway by human papillomaviruses of the alpha genus. The infection is thought to occur by vertical transmission at birth.
Evidence & references
- ECO:0000269 PubMed:31484767 ↗
The disease may be caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Respiratory papillomatosis, juvenile recurrent, congenital",
"diseaseAccession": "DI-05784",
"acronym": "JRRP",
"description": "An autosomal recessive disease characterized by recurrent growth of papillomas in the respiratory tract, and onset in early childhood. Papillomas are most commonly found in the larynx but may occur anywhere from the mouth to the bronchi. Children typically present within the first years of life with hoarseness or, in more severe cases, respiratory distress or stridor and airway obstruction. JRRP is associated with infection of the upper airway by human papillomaviruses of the alpha genus. The infection is thought to occur by vertical transmission at birth.",
"diseaseCrossReference": {
"database": "MIM",
"id": "618803"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "31484767"
}
]
},
"note": {
"texts": [
{
"value": "The disease may be caused by variants affecting the gene represented in this entry"
}
]
}
}Natural variants 17
Scroll across the table for evidence and actions.
17 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| A54TVAR_078798 | 54 | in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP:rs1057519492 A → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| A66VVAR_078799 | 66 | in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP:rs1057519493 A → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M77TVAR_069901 | 77 | in MSPC; destabilization of the N-terminal fragment; dbSNP:rs397514692 M → T | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| L155HVAR_033239 | 155 | risk factor for VAMAS1; dbSNP:rs12150220 L → H | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| T246SVAR_024238 | 246 | in dbSNP:rs11651595 T → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R404QVAR_021886 | 404 | in dbSNP:rs3744718 R → Q | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| R726WVAR_078800 | 726 | in AIADK; uncertain significance; dbSNP:rs776245016 R → W | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T755NVAR_083844 | 755 | in JRRP; gain-of-function variant resulting in spontaneous inflammasome activation; increased NLRP1-inflammasome complex assembly T → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Natural variantVAR_078801 | 787–843 | in MSPC; increased NLRP1-inflammasome complex assembly | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T878MVAR_033240 | 878 | in dbSNP:rs11657747 T → M | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V1059MVAR_024239 | 1059 | in dbSNP:rs2301582 V → M | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| H1069YVAR_033241 | 1069 | in dbSNP:rs9907167 H → Y | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| M1119VVAR_033242 | 1119 | no effect on autocatalytic processing, nor on IL1B release; dbSNP:rs35596958 M → V | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| M1184VVAR_033243 | 1184 | increased autocatalytic processing and IL1B release; dbSNP:rs11651270 M → V | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| P1214RVAR_078802 | 1214 | in AIADK; decreased interaction with DPP9, leading to increased inflammasome activity; dbSNP:rs1057524876 P → R | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| V1241LVAR_033244 | 1241 | in dbSNP:rs11653832 V → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1366CVAR_020437 | 1366 | in dbSNP:rs2137722 R → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Laboratory mutagenesis 69
Scroll across the table for evidence and actions.
69 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Q76A | 76 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q85A | 85 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q87A | 87 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q110A | 110 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q130A | 130 | Inhibits cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q130P | 130 | Inhibits cleavage by Protease 3C from Coxsackievirus B3 and HRV-14. Q → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q139A | 139 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q158A | 158 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q171A | 171 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| TST178AAA | 178–180 | In 3A mutant; abolished activation of the NLRP1 inflammasome in response to UV-B irradiation and ribosome collisions. TST → AAA | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q191A | 191 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q199A | 199 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q205A | 205 | No effect on cleavage by HRV-14 Protease 3C. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q333A | 333 | Abolished cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2. Q → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| GK339EA | 339–340 | Loss of ATP binding. GK → EA | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K340L / K340S | 340 | No effect. K → L, S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1168A | 1168 | Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine. H → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1186A | 1186 | Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing can be restored by treatment with hydroxylamine. H → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| LL1193EE | 1193–1194 | Reduced autocatalytic processing and reduced interaction with DPP9. LL → EE | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1211A | 1211 | Partial loss of autocatalytic processing and of IL1B release. S → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F1212A | 1212 | Complete loss of autocatalytic processing and of IL1B release. F → A | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| S1213A | 1213 | Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine. Abolished interaction with DPP9. Loss of activation by dsRNA or positive-strand RNA virus. S → A | Experimental evidence 6 publications Evidence & references
| No verified residues in this structure |
| S1213C | 1213 | Complete loss of autocatalytic processing, which can be restored by treatment with hydroxylamine. S → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P1214A | 1214 | Partial loss of autocatalytic processing (50%) and of IL1B release (50%). P → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1240D | 1240 | Slightly reduced formation of an inflammasome filament together with PYCARD/ASC. R → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1249A | 1249 | Complete loss of autocatalytic processing and IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine. H → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| RK1260DD | 1260–1261 | Slightly reduced formation of an inflammasome filament together with PYCARD/ASC. RK → DD | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1276G | 1276 | Abolished ability to form the NLRP1 inflammasome. H → G | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1277E | 1277 | Abolished ability to form the NLRP1 inflammasome. K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| PP1278AG | 1278–1279 | Abolished formation of an inflammasome filament together with PYCARD/ASC. PP → AG | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P1278E | 1278 | Impaired ability to form the NLRP1 inflammasome. P → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L1281E | 1281 | Impaired ability to form the NLRP1 inflammasome. L → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F1320A | 1320 | Slightly reduced formation of an inflammasome filament together with PYCARD/ASC. F → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1322R | 1322 | Abolished ability to form the NLRP1 inflammasome. E → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D1383R | 1383 | Abolished formation of an inflammasome filament together with PYCARD/ASC. D → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1386D | 1386 | Abolished formation of an inflammasome filament together with PYCARD/ASC. R → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1387R | 1387 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q1388D | 1388 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. Q → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1392D | 1392 | Abolished formation of an inflammasome filament together with PYCARD/ASC. R → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1392E | 1392 | Impaired ability to induce programmed cell death. R → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1395R | 1395 | Abolished formation of an inflammasome filament together with PYCARD/ASC. S → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1397R | 1397 | Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| D1401R | 1401 | Impaired ability to induce programmed cell death. D → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1402D | 1402 | Abolished formation of an inflammasome filament together with PYCARD/ASC. K → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1402E | 1402 | Abolished formation of an inflammasome filament together with PYCARD/ASC. K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1404D | 1404 | Abolished formation of an inflammasome filament together with PYCARD/ASC. H → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q1406R | 1406 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. Q → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q1410R | 1410 | Abolished formation of an inflammasome filament together with PYCARD/ASC. Q → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1411R | 1411 | Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Y1413R | 1413 | Abolished formation of an inflammasome filament together with PYCARD/ASC. Y → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1414R | 1414 | Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| R1415D | 1415 | Abolished formation of an inflammasome filament together with PYCARD/ASC. R → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N1420E | 1420 | Abolished formation of an inflammasome filament together with PYCARD/ASC. N → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1422E | 1422 | Abolished formation of an inflammasome filament together with PYCARD/ASC. R → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1427D | 1427 | Abolished formation of an inflammasome filament together with PYCARD/ASC. R → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R1427E | 1427 | Impaired ability to induce programmed cell death. R → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1428E | 1428 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q1434R | 1434 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. Q → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D1437R | 1437 | Abolished formation of an inflammasome filament together with PYCARD/ASC. D → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Y1445A | 1445 | Abolished inflammasome filament formation. Impaired ability to induce programmed cell death, but retains CAPS1 processing. Y → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1449D | 1449 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. K → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1450R | 1450 | Abolished formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T1451R | 1451 | Abolished formation of an inflammasome filament together with PYCARD/ASC. T → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1454D | 1454 | Abolished formation of an inflammasome filament together with PYCARD/ASC. H → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H1454E | 1454 | Abolished formation of an inflammasome filament together with PYCARD/ASC. H → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M1457A | 1457 | Does not affect ability to induce programmed cell death. M → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1458R | 1458 | Abolished formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W1460A | 1460 | Does not affect ability to induce programmed cell death. W → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1461R | 1461 | Does not affect formation of an inflammasome filament together with PYCARD/ASC. E → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
PTM/Processing
Autocatalytically cleaved [22, 10, 50]. Autocatalytic cleavage in FIIND region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding [22, 10, 50]. Both N- and C-terminal parts remain associated non-covalently [22, 10, 50]
Evidence & references
- ECO:0000269 PubMed:22087307 ↗
- ECO:0000269 PubMed:22665479 ↗
- ECO:0000269 PubMed:33093214 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22087307"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
}
],
"value": "Autocatalytically cleaved (PubMed:22087307, PubMed:22665479, PubMed:33093214). Autocatalytic cleavage in FIIND region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding (PubMed:22087307, PubMed:22665479, PubMed:33093214). Both N- and C-terminal parts remain associated non-covalently (PubMed:22087307, PubMed:22665479, PubMed:33093214)"
}
],
"commentType": "PTM",
"molecule": "NACHT, LRR and PYD domains-containing protein 1"
}Ubiquitinated by the cullin:ZER1/ZYG11B complex in response to pathogen-associated signals, leading to its degradation by the proteasome and subsequent release of the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome
Evidence & references
- ECO:0000269 PubMed:33093214 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
}
],
"value": "Ubiquitinated by the cullin:ZER1/ZYG11B complex in response to pathogen-associated signals, leading to its degradation by the proteasome and subsequent release of the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome"
}
],
"commentType": "PTM",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}Phosphorylated by MAP3K20 isoform ZAKalpha, MAPK11 and MAPK14 in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis
Evidence & references
- ECO:0000269 PubMed:35857590 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35857590"
}
],
"value": "Phosphorylated by MAP3K20 isoform ZAKalpha, MAPK11 and MAPK14 in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis"
}
],
"commentType": "PTM"
}(Microbial infection) Cleaved between Gln-130 and Gly-131 by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16) [50, 35]. This cleavage triggers N-glycine-mediated proteasomal degradation of the autoinhibitory NLRP1 N-terminal fragment via the cullin:ZER1/ZYG11B complex which liberates the activating C-terminal fragment and activates NLRP1 inflammasome [50]
Evidence & references
- ECO:0000269 PubMed:33093214 ↗
- ECO:0000269 PubMed:33410748 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33410748"
}
],
"value": "(Microbial infection) Cleaved between Gln-130 and Gly-131 by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16) (PubMed:33093214, PubMed:33410748). This cleavage triggers N-glycine-mediated proteasomal degradation of the autoinhibitory NLRP1 N-terminal fragment via the cullin:ZER1/ZYG11B complex which liberates the activating C-terminal fragment and activates NLRP1 inflammasome (PubMed:33093214)"
}
],
"commentType": "PTM"
}(Microbial infection) Cleaved between Gln-333 and Gly-334 by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2 [36]. This cleavage liberates the activating C-terminal fragment and activates NLRP1 inflammasome, leading to downstream activation of GSDME and lung epithelial cell death [36]
Evidence & references
- ECO:0000269 PubMed:35594856 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35594856"
}
],
"value": "(Microbial infection) Cleaved between Gln-333 and Gly-334 by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2 (PubMed:35594856). This cleavage liberates the activating C-terminal fragment and activates NLRP1 inflammasome, leading to downstream activation of GSDME and lung epithelial cell death (PubMed:35594856)"
}
],
"commentType": "PTM"
}Processed chains & precursor regions 3
Scroll across the table for evidence and actions.
3 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| ChainPRO_0000096710 | 1–1473 | NACHT, LRR and PYD domains-containing protein 1 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| ChainPRO_0000452851 | 1–1212 | NACHT, LRR and PYD domains-containing protein 1, N-terminus | Curator inference 1 publication Evidence & references
| No verified residues in this structure |
| ChainPRO_0000452852 | 1213–1473 | NACHT, LRR and PYD domains-containing protein 1, C-terminus | Curator inference 1 publication Evidence & references
| No verified residues in this structure |
Modifications 16
Scroll across the table for evidence and actions.
16 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Modified residue | 93 | Phosphoserine; by MAPK11 and MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 99 | Phosphoserine; by MAPK11 and MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 101 | Phosphoserine; by MAPK11 and MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 107 | Phosphoserine; by MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 112 | Phosphothreonine; by MAPK11, MAPK14 and MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 113 | Phosphoserine; by MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 114 | Phosphothreonine; by MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 129 | Phosphothreonine; by MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 132 | Phosphoserine; by MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 163 | Phosphoserine; by MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 168 | Phosphoserine; by MAPK11 and MAPk14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 170 | Phosphoserine; by MAPK11 and MAPK14 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 173 | Phosphoserine; by MAPK11 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 178 | Phosphothreonine; by MAPK11 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 179 | Phosphoserine; by MAPK11 and MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 180 | Phosphothreonine; by MAPK11 and MAP3K20 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Expression
Widely expressed [4, 17]. Abundantly expressed in primary immune cells (isoform 1 and isoform 2), including in neutrophils, monocytes/macrophages, dendritic cells (mostly Langerhans cells), and B- and T-lymphocytes (at protein level) [13, 17]. Strongly expressed in epithelial cells lining the glandular epithelium, such as that of the gastrointestinal tract (stomach, small intestine, colon), the respiratory tract (trachea and bronchi), and the endometrial and endocervical glands, gallbladder, prostate, and breast (at protein level).
In testis, expressed in spermatogonia and primary spermatocytes, but not in Sertoli cells (at protein level). In the brain, expressed in neurons, in particular in pyramidal ones and in oligodendrocytes, but not detected in microglia (at protein level) [17]. Expressed in adult and fetal ocular tissues, including in adult and 24-week old fetal choroid, sclera, cornea, and optic nerve, as well as in adult retina and fetal retina/retinal pigment epithelium [46].
Highly expressed in the skin throughout the epidermis and in dermal fibroblasts, in both glabrous skin and plantar skin. It is detected in keratinocytes, but not in melanocytes. Expressed in epidermal appendages such as hair follicles [47]
Evidence & references
- ECO:0000269 PubMed:11113115 ↗
- ECO:0000269 PubMed:15285719 ↗
- ECO:0000269 PubMed:17164409 ↗
- ECO:0000269 PubMed:23349227 ↗
- ECO:0000269 PubMed:27662089 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11113115"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15285719"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17164409"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23349227"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27662089"
}
],
"value": "Widely expressed (PubMed:11113115, PubMed:17164409). Abundantly expressed in primary immune cells (isoform 1 and isoform 2), including in neutrophils, monocytes/macrophages, dendritic cells (mostly Langerhans cells), and B- and T-lymphocytes (at protein level) (PubMed:15285719, PubMed:17164409). Strongly expressed in epithelial cells lining the glandular epithelium, such as that of the gastrointestinal tract (stomach, small intestine, colon), the respiratory tract (trachea and bronchi), and the endometrial and endocervical glands, gallbladder, prostate, and breast (at protein level). In testis, expressed in spermatogonia and primary spermatocytes, but not in Sertoli cells (at protein level). In the brain, expressed in neurons, in particular in pyramidal ones and in oligodendrocytes, but not detected in microglia (at protein level) (PubMed:17164409). Expressed in adult and fetal ocular tissues, including in adult and 24-week old fetal choroid, sclera, cornea, and optic nerve, as well as in adult retina and fetal retina/retinal pigment epithelium (PubMed:23349227). Highly expressed in the skin throughout the epidermis and in dermal fibroblasts, in both glabrous skin and plantar skin. It is detected in keratinocytes, but not in melanocytes. Expressed in epidermal appendages such as hair follicles (PubMed:27662089)"
}
],
"commentType": "TISSUE SPECIFICITY"
}Developmental stage
Associated with differentiation in stratified epithelia of the skin, esophagus, intestine, and cervix, as well as in the prostate gland. Undetectable in undifferentiated basal cells, but expressed in differentiated luminal secretory cells [4]. Expressed in differentiated macrophages and granulocytes, but not their precursors (at protein level) [4, 13].
In testis, also associated with cell differentiation, with conflicting results. Expressed in spermatogonia and primary spermatocytes, but not in cells from later differentiation stages, including secondary spermatocytes, spermatids, and spermatozoa (at protein level) [17]. Not detected in spermatocytes, nor spermatids, and strongly expressed in spermatozoa (at protein level) [4]
Evidence & references
- ECO:0000269 PubMed:11113115 ↗
- ECO:0000269 PubMed:15285719 ↗
- ECO:0000269 PubMed:17164409 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11113115"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15285719"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17164409"
}
],
"value": "Associated with differentiation in stratified epithelia of the skin, esophagus, intestine, and cervix, as well as in the prostate gland. Undetectable in undifferentiated basal cells, but expressed in differentiated luminal secretory cells (PubMed:11113115). Expressed in differentiated macrophages and granulocytes, but not their precursors (at protein level) (PubMed:11113115, PubMed:15285719). In testis, also associated with cell differentiation, with conflicting results. Expressed in spermatogonia and primary spermatocytes, but not in cells from later differentiation stages, including secondary spermatocytes, spermatids, and spermatozoa (at protein level) (PubMed:17164409). Not detected in spermatocytes, nor spermatids, and strongly expressed in spermatozoa (at protein level) (PubMed:11113115)"
}
],
"commentType": "DEVELOPMENTAL STAGE"
}Induction
Up-regulated by ATF4 during endoplasmic reticulum (ER) stress response [28]. Up-regulated in arterial endothelial cells exposed to plasma from patients with peripheral arterial disease, but not to plasma from healthy controls [25]
Evidence & references
- ECO:0000269 PubMed:24439873 ↗
- ECO:0000269 PubMed:26086088 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24439873"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26086088"
}
],
"value": "Up-regulated by ATF4 during endoplasmic reticulum (ER) stress response (PubMed:26086088). Up-regulated in arterial endothelial cells exposed to plasma from patients with peripheral arterial disease, but not to plasma from healthy controls (PubMed:24439873)"
}
],
"commentType": "INDUCTION"
}Interaction
Documented interaction partners
UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.
| Partner / product | Species | Experiments | Evidence & actions |
|---|---|---|---|
| BCL2P10415With Q9C000 | Homo sapiens | 13 | IntAct evidenceSource product: Q9C000. Partner: P10415. Reported experiment count: 13. |
| BCL2L1Q07817With Q9C000 | Homo sapiens | 9 | IntAct evidenceSource product: Q9C000. Partner: Q07817. Reported experiment count: 9. |
| BCL2L1Q07817-1With Q9C000 | Homo sapiens | 2 | IntAct evidenceSource product: Q9C000. Partner: Q07817-1. Reported experiment count: 2. |
| CASP1P29466With Q9C000 | Homo sapiens | 3 | IntAct evidenceSource product: Q9C000. Partner: P29466. Reported experiment count: 3. |
| PYCARDQ9ULZ3With Q9C000 | Homo sapiens | 5 | IntAct evidenceSource product: Q9C000. Partner: Q9ULZ3. Reported experiment count: 5. |
No partners match this filter.
Complex membership & assembly descriptions
Co-membership does not by itself prove direct binding between every pair.
NLRP1 inflammasome CPX-4082 Complex Portal
Homo sapiens; 9606 ·
Evidence: inferred by curator
- NLRP1 · Q9C000 ·
- CASP1 · P29466 ·
- PYCARD · Q9ULZ3 ·
A pro-inflammatory thiol protease complex that is activated in response to pathogen infections and toxins (e.g. Anthrax lethal toxin). Primarily acts in monocytes and macrophages. Activating platform for Caspase-1 (CPX-952) through proximity-induced self-cleavage in an ATP-dependent reaction. Activated Caspase-1 cleaves interleukins 1beta (IL1B, P01584) and IL18 (Q14116) releasing the mature cytokines which are involved in a variety of inflammatory processes and is also involved in pyroptosis of macrophages, a special case of cell death, associated with infection by intracellular pathogens where it cleaves GSDMD (P57764). Belongs to the family of Inflammasomes that includes NLRP3 inflammasome (CPX-4141), NLRC4 inflammasome (CPX-4144), AIM2 inflammasome (CPX-4142) and Pyrin inflammasome (CPX-4143). Single-nucleotide polymorphisms in the NLRP1 gene are associated with vitiligo.
Source & references ↗UniProt subunit description
Interacts (via LRR repeats) with BCL2 and BCL2L1 (via the loop between motifs BH4 and BH3); these interactions reduce NLRP1 inflammasome-induced CASP1 activation and IL1B release, possibly by impairing NLRP1 interaction with PYCARD [15]. Interacts with NOD2; this interaction is enhanced in the presence of muramyl dipeptide (MDP) and increases IL1B release [19]. Interacts with EIF2AK2/PKR; this interaction requires EIF2AK2 activity, is accompanied by EIF2AK2 autophosphorylation and promotes inflammasome assembly in response to danger-associated signals [23].
Interacts with MEFV; this interaction targets NLRP1 to degradation by autophagy, hence preventing excessive IL1B- and IL18-mediated inflammation [16, 26]. Binds (via LRR domain) to dsDNA and dsRNA [33]. Interacts with DPP9; leading to inhibit activation of the inflammasome [29, 31, 42].
DPP9 acts via formation of a ternary complex, composed of a DPP9 homodimer, one full-length NLRP1 protein, and one cleaved C-terminus of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) [42]. Interacts with DPP8; leading to inhibit activation of the inflammasome, probably via formation of a ternary complex with DPP8 [31]
Evidence & references
- ECO:0000269 PubMed:17418785 ↗
- ECO:0000269 PubMed:17431422 ↗
- ECO:0000269 PubMed:18511561 ↗
- ECO:0000269 PubMed:22801494 ↗
- ECO:0000269 PubMed:26347139 ↗
- ECO:0000269 PubMed:30291141 ↗
- ECO:0000269 PubMed:31525884 ↗
- ECO:0000269 PubMed:33243852 ↗
- ECO:0000269 PubMed:33731932 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17418785"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17431422"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18511561"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22801494"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26347139"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "30291141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "31525884"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33731932"
}
],
"value": "Interacts (via LRR repeats) with BCL2 and BCL2L1 (via the loop between motifs BH4 and BH3); these interactions reduce NLRP1 inflammasome-induced CASP1 activation and IL1B release, possibly by impairing NLRP1 interaction with PYCARD (PubMed:17418785). Interacts with NOD2; this interaction is enhanced in the presence of muramyl dipeptide (MDP) and increases IL1B release (PubMed:18511561). Interacts with EIF2AK2/PKR; this interaction requires EIF2AK2 activity, is accompanied by EIF2AK2 autophosphorylation and promotes inflammasome assembly in response to danger-associated signals (PubMed:22801494). Interacts with MEFV; this interaction targets NLRP1 to degradation by autophagy, hence preventing excessive IL1B- and IL18-mediated inflammation (PubMed:17431422, PubMed:26347139). Binds (via LRR domain) to dsDNA and dsRNA (PubMed:33243852). Interacts with DPP9; leading to inhibit activation of the inflammasome (PubMed:30291141, PubMed:31525884, PubMed:33731932). DPP9 acts via formation of a ternary complex, composed of a DPP9 homodimer, one full-length NLRP1 protein, and one cleaved C-terminus of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) (PubMed:33731932). Interacts with DPP8; leading to inhibit activation of the inflammasome, probably via formation of a ternary complex with DPP8 (PubMed:31525884)"
}
],
"commentType": "SUBUNIT"
}Interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in absence of pathogens and other damage-associated signals
Evidence & references
- ECO:0000269 PubMed:33093214 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
}
],
"value": "Interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in absence of pathogens and other damage-associated signals"
}
],
"commentType": "SUBUNIT",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}Interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus) in absence of pathogens and other damage-associated signals [50]. Homomultimer; forms the NLRP1 inflammasome polymeric complex, a filament composed of homopolymers of this form in response to pathogens and other damage-associated signals [43, 44]. The NLRP1 inflammasome polymeric complex associates with PYCARD/ASC [12, 18, 15, 10].
Interacts (via CARD domain) with PYCARD/ASC (via CARD domain); leading to pro-caspase-1 (proCASP1) recruitment [12, 15, 10]. Pro-caspase-1 (proCASP1) filament formation increases local enzyme concentration, resulting in trans-autocleavage and activation [12, 18, 10]. Active CASP1 then processes IL1B and IL18 precursors, leading to the release of mature cytokines in the extracellular milieu and inflammatory response [12, 18, 10]
Evidence & references
- ECO:0000269 PubMed:12191486 ↗
- ECO:0000269 PubMed:17349957 ↗
- ECO:0000269 PubMed:17418785 ↗
- ECO:0000269 PubMed:22665479 ↗
- ECO:0000269 PubMed:33093214 ↗
- ECO:0000269 PubMed:33420028 ↗
- ECO:0000269 PubMed:33420033 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12191486"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17349957"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17418785"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33093214"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33420028"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33420033"
}
],
"value": "Interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus) in absence of pathogens and other damage-associated signals (PubMed:33093214). Homomultimer; forms the NLRP1 inflammasome polymeric complex, a filament composed of homopolymers of this form in response to pathogens and other damage-associated signals (PubMed:33420028, PubMed:33420033). The NLRP1 inflammasome polymeric complex associates with PYCARD/ASC (PubMed:12191486, PubMed:17349957, PubMed:17418785, PubMed:22665479). Interacts (via CARD domain) with PYCARD/ASC (via CARD domain); leading to pro-caspase-1 (proCASP1) recruitment (PubMed:12191486, PubMed:17418785, PubMed:22665479). Pro-caspase-1 (proCASP1) filament formation increases local enzyme concentration, resulting in trans-autocleavage and activation (PubMed:12191486, PubMed:17349957, PubMed:22665479). Active CASP1 then processes IL1B and IL18 precursors, leading to the release of mature cytokines in the extracellular milieu and inflammatory response (PubMed:12191486, PubMed:17349957, PubMed:22665479)"
}
],
"commentType": "SUBUNIT",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}(Microbial infection) Interacts with vaccinia virus protein F1 [24]
Evidence & references
- ECO:0000269 PubMed:16439990 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16439990"
}
],
"value": "(Microbial infection) Interacts with vaccinia virus protein F1 (PubMed:16439990)"
}
],
"commentType": "SUBUNIT"
}(Microbial infection) Interacts with human herpes virus 8/HHV-8 proteins ORF45; relieving autoinhibition of the NLRP1 inflammasome
Evidence & references
- ECO:0000269 PubMed:35618833 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35618833"
}
],
"value": "(Microbial infection) Interacts with human herpes virus 8/HHV-8 proteins ORF45; relieving autoinhibition of the NLRP1 inflammasome"
}
],
"commentType": "SUBUNIT",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}Other association resources
Resource links only; their association networks and counts are not added to the partner table.
Structure
6X6C · Cryo-EM structure of NLRP1-DPP9-VbP complex
ELECTRON MICROSCOPY · 2.9 Å
Recorded components
| Component | Species | Chains | Protein identities |
|---|---|---|---|
| Dipeptidyl peptidase 9protein · Entity 1 | Homo sapiens | A, B | Q86TI2 |
| NACHT, LRR and PYD domains-containing protein 1protein · Entity 2 | Homo sapiens | C, D | Q9C000 |
| [(2~{R})-1-[(2~{R})-2-azanyl-3-methyl-butanoyl]pyrrolidin-2-yl]boronic acidligand · Entity 3 | E, F | No verified protein mapping |
Biological assemblies
Assembly 1 · author_defined_assembly
Recorded chains: A, B, C, D, E, F
Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.
Publication
DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation.
17/03/2021 · Read publication ↗
Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.
PDB source record ↗Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.
Available structures 13
Scroll across the table for evidence and actions.
13 recorded rows
| Record | Evidence type | Method | Resolution | Open |
|---|---|---|---|---|
| 6X6C | experimental | EM | 2.90 A | Open in Atlas ↗ |
| 6X6A | experimental | EM | 3.60 A | Open in Atlas ↗ |
| 7WGE | experimental | EM | 3.40 A | Open in Atlas ↗ |
| 4IM6 | experimental | X-ray | 1.65 A | Open in Atlas ↗ |
| 8ZGD | experimental | X-ray | 2.05 A | Open in Atlas ↗ |
| 5Y3S | experimental | X-ray | 2.45 A | Open in Atlas ↗ |
| 4IFP | experimental | X-ray | 1.99 A | Open in Atlas ↗ |
| 3KAT | experimental | X-ray | 3.10 A | Open in Atlas ↗ |
| 6XKK | experimental | EM | 3.60 A | Open in Atlas ↗ |
| 6K7V | experimental | EM | 3.70 A | Open in Atlas ↗ |
| 1PN5 | experimental | NMR | - | Open in Atlas ↗ |
| 9BJ9 | experimental | EM | 4.20 A | Open in Atlas ↗ |
| AF-Q9C000-F1 | predicted | AlphaFold | Not applicable | Open in Atlas ↗ |
Family & Domains
The CARD domain, rather than the pyrin domain, is involved in the interaction with PYCARD, CASP1 and CASP5
Evidence & references
- ECO:0000269 PubMed:12191486 ↗
- ECO:0000269 PubMed:17349957 ↗
- ECO:0000269 PubMed:22665479 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12191486"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17349957"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
}
],
"value": "The CARD domain, rather than the pyrin domain, is involved in the interaction with PYCARD, CASP1 and CASP5"
}
],
"commentType": "DOMAIN"
}The ZAKalpha motifs are recognized and phosphorylated by isoform ZAKalpha of MAP3K20
Evidence & references
- ECO:0000269 PubMed:35857590 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "35857590"
}
],
"value": "The ZAKalpha motifs are recognized and phosphorylated by isoform ZAKalpha of MAP3K20"
}
],
"commentType": "DOMAIN"
}The leucine-rich repeat (LRR) domain may be involved in autoinhibition in the absence of activating signal, possibly through intramolecular interaction with the NACHT domain. Serves as the predominant binding domain for dsRNA and dsDNA [33]
Evidence & references
- ECO:0000250 UniProtKB:Q9EPB4
- ECO:0000269 PubMed:12191486 ↗
- ECO:0000269 PubMed:17349957 ↗
- ECO:0000269 PubMed:33243852 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "Q9EPB4"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12191486"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17349957"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
],
"value": "The leucine-rich repeat (LRR) domain may be involved in autoinhibition in the absence of activating signal, possibly through intramolecular interaction with the NACHT domain. Serves as the predominant binding domain for dsRNA and dsDNA (PubMed:33243852)"
}
],
"commentType": "DOMAIN"
}The FIIND (domain with function to find) region is involved in homomerization, but not in CASP1-binding (By similarity). Autocatalytic cleavage in this region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding [22, 10]. Both N- and C-terminal fragments remain associated [22, 10]
Evidence & references
- ECO:0000250 UniProtKB:Q2LKW6
- ECO:0000269 PubMed:22087307 ↗
- ECO:0000269 PubMed:22665479 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "Q2LKW6"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22087307"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "22665479"
}
],
"value": "The FIIND (domain with function to find) region is involved in homomerization, but not in CASP1-binding (By similarity). Autocatalytic cleavage in this region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding (PubMed:22087307, PubMed:22665479). Both N- and C-terminal fragments remain associated (PubMed:22087307, PubMed:22665479)"
}
],
"commentType": "DOMAIN"
}The pyrin domain mediates an autoinhibitory function, potentially acting as a threshold modulator, which allows NLRP1 to discriminate long from short dsRNA. Inhibits ATPase activity of the NATCH domain
Evidence & references
- ECO:0000269 PubMed:33243852 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
],
"value": "The pyrin domain mediates an autoinhibitory function, potentially acting as a threshold modulator, which allows NLRP1 to discriminate long from short dsRNA. Inhibits ATPase activity of the NATCH domain"
}
],
"commentType": "DOMAIN"
}The C-terminal part of NLRP1 oligomerizes to form the core of the NLRP1 inflammasome filament: in the filament, the CARD domains form a central helical filaments that are promoted by oligomerized, but flexibly linked, UPA regions surrounding the filaments [43, 44]. The UPA region reduces the threshold needed for filament formation and signaling [43, 44]. Must recruit the adapter PYCARD/ASC to facilitate CASP1 interaction and polymerization [44]
Evidence & references
- ECO:0000269 PubMed:33420028 ↗
- ECO:0000269 PubMed:33420033 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33420028"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33420033"
}
],
"value": "The C-terminal part of NLRP1 oligomerizes to form the core of the NLRP1 inflammasome filament: in the filament, the CARD domains form a central helical filaments that are promoted by oligomerized, but flexibly linked, UPA regions surrounding the filaments (PubMed:33420028, PubMed:33420033). The UPA region reduces the threshold needed for filament formation and signaling (PubMed:33420028, PubMed:33420033). Must recruit the adapter PYCARD/ASC to facilitate CASP1 interaction and polymerization (PubMed:33420033)"
}
],
"commentType": "DOMAIN",
"molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}Upon dsRNA-binding via its LRR domain, NACHT domain gains ATPase activity which is inhibited by the pyrin domain
Evidence & references
- ECO:0000269 PubMed:33243852 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "33243852"
}
],
"value": "Upon dsRNA-binding via its LRR domain, NACHT domain gains ATPase activity which is inhibited by the pyrin domain"
}
],
"commentType": "DOMAIN"
}Belongs to the NLRP family
Evidence & references
- ECO:0000305
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000305"
}
],
"value": "Belongs to the NLRP family"
}
],
"commentType": "SIMILARITY"
}Domain architecture
Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.
Atlas domains, motifs & repeats 18
Scroll across the table for evidence and actions.
18 recorded rows
| Annotation | Position | Source & interpretation | Inspect |
|---|---|---|---|
| DAPIN domainIPR004020 | 1–92 | INTERPROdomain The DAPIN (Domain in Apoptosis and INterferon response) domain is an 80-100- residue domain which is found in the N terminus of diverse vertebrate and vertebrate-specific viral proteins involved in apoptosis, cancer, inflammation, and immune response. The DAPIN domain can be found alone or in association with other domains like CARD, LRR, SPRY, Caspase or Zinc finger B-box. Full source descriptionThe DAPIN (Domain in Apoptosis and INterferon response) domain is an 80-100- residue domain which is found in the N terminus of diverse vertebrate and vertebrate-specific viral proteins involved in apoptosis, cancer, inflammation, and immune response. The DAPIN domain can be found alone or in association with other domains like CARD, LRR, SPRY, Caspase or Zinc finger B-box. It has been proposed that the DAPIN domain might have an adaptor function, coupling apoptosis and immune disorders. It has been shown that the DAPIN domain is a protein-protein interaction domain capable of binding to other DAPIN domains. Secondary structure predictions have identified the DAPIN domain as mostly α-helical and it has been suggested that it could belong to the DEATH- domain-fold superfamily, which includes the CARD, the DEATH domain (DD) and the DEATH effector domain (DED). The DAPIN domain has also been called pyrin domain, pyrin N-terminal homology domain (PYD) or PAAD (after the protein families pyrin, AIM, ASC death-domain- like). | No verified residues in this structure |
| NACHT nucleoside triphosphataseIPR007111 | 328–637 | INTERPROdomain The NACHT domain is a 300 to 400 residue predicted nucleoside triphosphatase (NTPase) domain, which is found in animal, fungal and bacterial proteins. The NACHT domain has been named after NAIP, CIITA, HET-E and TP1. Full source descriptionThe NACHT domain is a 300 to 400 residue predicted nucleoside triphosphatase (NTPase) domain, which is found in animal, fungal and bacterial proteins. The NACHT domain has been named after NAIP, CIITA, HET-E and TP1. It is found in association with other domains, such as the CARD domain ([interpro:IPR001315]), the DAPIN domain ([interpro:IPR004020]), the HEAT repeat ([interpro:IPR004155]), the WD repeat ([interpro:IPR001680]), the leucine-rich repeat (LRR) or the BIR repeat ([interpro:IPR001370]). The NACHT domain consists of seven distinct conserved motifs, including the ATP/GTPase specific P-loop, the Mg(2+)-binding site (Walker A and B motifs, respectively) and five more specific motifs. The unique features of the NACHT domain include the prevalence of 'tiny' residues (glycine, alanine or serine) directly C-terminal of the Mg(2+)-coordinating aspartate in the Walker B motif, in place of a second acidic residue prevalent in other NTPases. A second acidic residue is typically found in the NACHT-containing proteins two positions downstream. Furthermore, the distal motif VII contains a conserved pattern of polar, aromatic and hydrophobic residues that is not seen in any other NTPase family. | No verified residues in this structure |
| NOD1/2, winged helix domainIPR041075 | 567–615 | INTERPROdomain This winged helix domain is found in the NOD1, NOD2 and related proteins that play a role in immune response. In NLRP3, this domain is important for ATB binding. Source entry ↗ | No verified residues in this structure |
| NACHT, LRR and PYD domains-containing protein, helical domain HD2IPR041267 | 623–733 | INTERPROdomain This entry represents the second of two helical domains (HD2) found in the NLRC proteins, the NOD2 protein and NACHT, LRR and PYD domains-containing proteins. Source entry ↗ | No verified residues in this structure |
| Leucine rich repeat, ribonuclease inhibitor typeSM00368 | 807–834 | SMARTdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| LRR RegionCLUSTER_LRR_809_973 | 809–973 | ALPHASUITEdomain 6 LRR repeats grouped into a tandem region. | No verified residues in this structure |
| Leucine-rich repeatIPR001611 | 809–830 | INTERPROrepeat Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Full source descriptionLeucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. | No verified residues in this structure |
| Leucine rich repeat, ribonuclease inhibitor typeSM00368 | 836–863 | SMARTdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| LRR 2UNI_REPEAT_838_858 | 838–858 | UNIPROTrepeat LRR 2 Source entry ↗ | No verified residues in this structure |
| Leucine rich repeat, ribonuclease inhibitor typeSM00368 | 864–891 | SMARTdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| Leucine-rich repeatIPR001611 | 864–886 | INTERPROrepeat Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Full source descriptionLeucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. | No verified residues in this structure |
| Leucine rich repeat, ribonuclease inhibitor typeSM00368 | 893–920 | SMARTdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| LRR 4UNI_REPEAT_895_915 | 895–915 | UNIPROTrepeat LRR 4 Source entry ↗ | No verified residues in this structure |
| Leucine rich repeat, ribonuclease inhibitor typeSM00368 | 921–948 | SMARTdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| Leucine-rich repeatIPR001611 | 921–943 | INTERPROrepeat Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Full source descriptionLeucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats. | No verified residues in this structure |
| LRR 6UNI_REPEAT_950_973 | 950–973 | UNIPROTrepeat LRR 6 Source entry ↗ | No verified residues in this structure |
| FIIND domainIPR025307 | 1079–1364 | INTERPROdomain This entry contains the whole FIIND domain [prosite:PS51830] composed by the ZU5 sub-domain [pfam:PF13553] and the UPA sub-domain [pfam:PF23679]. The so-called function-to-find (FIIND) domain was initially identified in two proteins: NLRP1 (also known as NALP1, CARD7, NAC, DEFCAP) and CARD8 (also known as TUCAN, Cardinal). Full source descriptionThis entry contains the whole FIIND domain [prosite:PS51830] composed by the ZU5 sub-domain [pfam:PF13553] and the UPA sub-domain [pfam:PF23679]. The so-called function-to-find (FIIND) domain was initially identified in two proteins: NLRP1 (also known as NALP1, CARD7, NAC, DEFCAP) and CARD8 (also known as TUCAN, Cardinal). NLRP1 is a member of the Nod-like receptor (NLR) protein superfamily and is involved in apoptosis and inflammation; to date, it remains the only NLR protein known to possess a FIIND domain. The domain is likewise present in CARD8, where, as in NLRP1, it is followed by a C-terminal CARD domain. Both proteins are reported to form an "inflammasome", a macromolecular complex capable of processing caspase-1 and activating pro-IL1β. The FIIND domain comprises two subdomains: ZU5 (found in the tight-junction protein ZO-1 and the netrin receptor UNC5) and UPA (conserved in UNC5, the death-domain-containing protein PIDD, and proteins of the ankyrin family). Notably, the FIIND domain is found in only a small subset of the animal kingdom, including primates, rodents (mouse, rat), carnivores (e.g., dog), and a few other species such as horses. Early studies describing NLRP1 did not initially recognise FIIND as a distinct domain, mistakenly identifying it as part of the adjacent leucine-rich repeat (LRR) domain. The discovery of CARD8 later revealed that its N-terminal region shared significant sequence identity with an uncharacterised region in NLRP1. Before receiving its current designation, the FIIND domain was referred to as the NALP1-associated domain (NAD). | No verified residues in this structure |
| CARD domainIPR001315 | 1380–1463 | INTERPROdomain The caspase recruitment domain (CARD domain) is a homotypic protein interaction module composed of a bundle of six α-helices. CARD is related in sequence and structure to the death domain (DD, see [interpro:IPR000488]) and the death effector domain (DED, see [interpro:IPR001875]), which work in similar pathways and show similar interaction properties. Full source descriptionThe caspase recruitment domain (CARD domain) is a homotypic protein interaction module composed of a bundle of six α-helices. CARD is related in sequence and structure to the death domain (DD, see [interpro:IPR000488]) and the death effector domain (DED, see [interpro:IPR001875]), which work in similar pathways and show similar interaction properties. The CARD domain typically associates with other CARD-containing proteins, forming either dimers or trimers. CARD domains can be found in isolation, or in combination with other domains. Domains associated with CARD include: NACHT ([interpro:IPR007111]) (in Nal1 and Bir1), NB-ARC ([interpro:IPR002182]) (in Apaf-1), pyrin/dapin domains ([interpro:IPR004020]) (in Nal1), leucine-rich repeats ([interpro:IPR001611]) (in Nal1), WD repeats ([interpro:IPR001680]) (in Apaf1), Src homology domains ([interpro:IPR001452]), PDZ ([interpro:IPR001478]), RING, kinase and DD domains. CARD-containing proteins are involved in apoptosis through their regulation of caspases that contain CARDs in their N-terminal pro-domains, including human caspases 1, 2, 9, 11 and 12. CARD-containing proteins are also involved in inflammation through their regulation of NF-kappaB. The mechanisms by which CARDs activate caspases and NF-kappaB involve the assembly of multi-protein complexes, which can facilitate dimerisation or serve as scaffolds on which proteases and kinases are assembled and activated. | No verified residues in this structure |
UniProt domains, repeats & motifs 12
Scroll across the table for evidence and actions.
12 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Domain | 1–92 | Pyrin | Sequence analysis Evidence & references
| No verified residues in this structure |
| Domain | 328–637 | NACHT | Sequence analysis Evidence & references
| No verified residues in this structure |
| Repeat | 809–830 | LRR 1 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 838–858 | LRR 2 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 866–887 | LRR 3 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 895–915 | LRR 4 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 923–944 | LRR 5 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 950–973 | LRR 6 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Domain | 1079–1364 | FIIND | Sequence analysis Evidence & references
| No verified residues in this structure |
| Domain | 1374–1463 | CARD | Sequence analysis Evidence & references
| No verified residues in this structure |
| Motif | 111–117 | ZAKalpha motif 1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Motif | 177–183 | ZAKalpha motif 2 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Functional sites 4
Scroll across the table for evidence and actions.
4 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Binding site | 334–341 | Binding site | Sequence analysis Evidence & references
| No verified residues in this structure |
| Site | 130–131 | (Microbial infection) Cleavage; by human rhinovirus 14 (HRV-14) Protease 3C | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Site | 333–334 | (Microbial infection) Cleavage; by coronavirus SARS-CoV-2 proteinase nsp5 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Site | 1212–1213 | Cleavage; by autolysis | Sequence analysisExperimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Sequence regions 7
Scroll across the table for evidence and actions.
7 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Region | 90–113 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 160–254 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 991–1017 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 1079–1212 | ZU5 | Published statement 1 publication Evidence & references
| No verified residues in this structure |
| Region | 1213–1364 | UPA | Published statement 1 publication Evidence & references
| No verified residues in this structure |
| Compositional bias | 170–182 | Polar residues | Evidence & references
| No verified residues in this structure |
| Compositional bias | 218–231 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
Sequence & Isoforms
Sequence & isoforms
UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.
The mass describes this unmodified source sequence, not every mature or modified product.
MAGGAWGRLACYLEFLKKEELKEFQLLLANKAHSRSSSGETPAQPEKTSGMEVASYLVAQYGEQRAWDLALHTWEQMGLRSLCAQAQEGAGHSPSFPYSPSEPHLGSPSQPTSTAVLMPWIHELPAGCTQGSERRVLRQLPDTSGRRWREISASLLYQALPSSPDHESPSQESPNAPTSTAVLGSWGSPPQPSLAPREQEAPGTQWPLDETSGIYYTEIREREREKSEKGRPPWAAVVGTPPQAHTSLQPHHHPWEPSVRESLCSTWPWKNEDFNQKFTQLLLLQRPHPRSQDPLVKRSWPDYVEENRGHLIEIRDLFGPGLDTQEPRIVILQGAAGIGKSTLARQVKEAWGRGQLYGDRFQHVFYFSCRELAQSKVVSLAELIGKDGTATPAPIRQILSRPERLLFILDGVDEPGWVLQEPSSELCLHWSQPQPADALLGSLLGKTILPEASFLITARTTALQNLIPSLEQARWVEVLGFSESSRKEYFYRYFTDERQAIRAFRLVKSNKELWALCLVPWVSWLACTCLMQQMKRKEKLTLTSKTTTTLCLHYLAQALQAQPLGPQLRDLCSLAAEGIWQKKTLFSPDDLRKHGLDGAIISTFLKMGILQEHPIPLSYSFIHLCFQEFFAAMSYVLEDEKGRGKHSNCIIDLEKTLEAYGIHGLFGASTTRFLLGLLSDEGEREMENIFHCRLSQGRNLMQWVPSLQLLLQPHSLESLHCLYETRNKTFLTQVMAHFEEMGMCVETDMELLVCTFCIKFSRHVKKLQLIEGRQHRSTWSPTMVVLFRWVPVTDAYWQILFSVLKVTRNLKELDLSGNSLSHSAVKSLCKTLRRPRCLLETLRLAGCGLTAEDCKDLAFGLRANQTLTELDLSFNVLTDAGAKHLCQRLRQPSCKLQRLQLVSCGLTSDCCQDLASVLSASPSLKELDLQQNNLDDVGVRLLCEGLRHPACKLIRLGLDQTTLSDEMRQELRALEQEKPQLLIFSRRKPSVMTPTEGLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPEVVPVELLCVPSPASQGDLHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVHFPVAGSYRWPNTGLCFVMREAVTVEIEFCVWDQFLGEINPQHSWMVAGPLLDIKAEPGAVEAVHLPHFVALQGGHVDTSLFQMAHFKEEGMLLEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPVTSVVLLYHRVHPEEVTFHLYLIPSDCSIRKAIDDLEMKFQFVRIHKPPPLTPLYMGCRYTVSGSGSGMLEILPKELELCYRSPGEDQLFSEFYVGHLGSGIRLQVKDKKDETLVWEALVKPGDLMPATTLIPPARIAVPSPLDAPQLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQYERVLAENTRPSQMRKLFSLSQSWDRKCKDGLYQALKETHPHLIMELWEKGSKKGLLPLSSSource isoform notes & selection
Alternative splicing
Complete source annotation
{
"commentType": "ALTERNATIVE PRODUCTS",
"events": [
"Alternative splicing"
],
"isoforms": [
{
"name": {
"value": "1"
},
"synonyms": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11113115"
}
],
"value": "NAC beta"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11076957"
}
],
"value": "DEFCAP-L"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "15285719"
}
],
"value": "NALP1-L"
}
],
"isoformIds": [
"Q9C000-1"
],
"isoformSequenceStatus": "Displayed"
},
{
"name": {
"value": "2"
},
"synonyms": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11113115"
}
],
"value": "NAC alpha"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11076957"
}
],
"value": "DEFCAP-S"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "15285719"
}
],
"value": "NALP1-S"
},
{
"value": "NLRP1deltaEx14"
}
],
"isoformIds": [
"Q9C000-2"
],
"sequenceIds": [
"VSP_004327"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "3"
},
"synonyms": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11113115"
}
],
"value": "NAC gamma"
}
],
"isoformIds": [
"Q9C000-3"
],
"sequenceIds": [
"VSP_004326",
"VSP_004327"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "4"
},
"synonyms": [
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "11113115"
}
],
"value": "NAC delta"
}
],
"isoformIds": [
"Q9C000-4"
],
"sequenceIds": [
"VSP_004326"
],
"isoformSequenceStatus": "Described"
},
{
"name": {
"value": "5"
},
"isoformIds": [
"Q9C000-5"
],
"sequenceIds": [
"VSP_053803",
"VSP_053804",
"VSP_053805"
],
"isoformSequenceStatus": "Described"
}
]
}- Q9C000-1 · 1 · Displayed · NAC beta, DEFCAP-L, NALP1-L
Complete source annotation
{ "name": { "value": "1" }, "synonyms": [ { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11113115" } ], "value": "NAC beta" }, { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11076957" } ], "value": "DEFCAP-L" }, { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "15285719" } ], "value": "NALP1-L" } ], "isoformIds": [ "Q9C000-1" ], "isoformSequenceStatus": "Displayed" } - Q9C000-2 · 2 · Described · NAC alpha, DEFCAP-S, NALP1-S, NLRP1deltaEx14 · VSP_004327
Complete source annotation
{ "name": { "value": "2" }, "synonyms": [ { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11113115" } ], "value": "NAC alpha" }, { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11076957" } ], "value": "DEFCAP-S" }, { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "15285719" } ], "value": "NALP1-S" }, { "value": "NLRP1deltaEx14" } ], "isoformIds": [ "Q9C000-2" ], "sequenceIds": [ "VSP_004327" ], "isoformSequenceStatus": "Described" } - Q9C000-3 · 3 · Described · NAC gamma · VSP_004326, VSP_004327
Complete source annotation
{ "name": { "value": "3" }, "synonyms": [ { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11113115" } ], "value": "NAC gamma" } ], "isoformIds": [ "Q9C000-3" ], "sequenceIds": [ "VSP_004326", "VSP_004327" ], "isoformSequenceStatus": "Described" } - Q9C000-4 · 4 · Described · NAC delta · VSP_004326
Complete source annotation
{ "name": { "value": "4" }, "synonyms": [ { "evidences": [ { "evidenceCode": "ECO:0000303", "source": "PubMed", "id": "11113115" } ], "value": "NAC delta" } ], "isoformIds": [ "Q9C000-4" ], "sequenceIds": [ "VSP_004326" ], "isoformSequenceStatus": "Described" } - Q9C000-5 · 5 · Described · VSP_053803, VSP_053804, VSP_053805
Complete source annotation
{ "name": { "value": "5" }, "isoformIds": [ "Q9C000-5" ], "sequenceIds": [ "VSP_053803", "VSP_053804", "VSP_053805" ], "isoformSequenceStatus": "Described" }
Isoform sequence differences 5
Scroll across the table for evidence and actions.
5 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Alternative sequenceVSP_004326 | 958–987 | in isoform 3 and isoform 4 | Published statement 1 publication Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_053803 | 1044 | in isoform 5 A → AGKSH | Published statement 2 publications Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_004327 | 1262–1305 | in isoform 2 and isoform 3 | Published statement 5 publications Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_053804 | 1354–1371 | in isoform 5 DLMPATTLIPPARIAVPS → RNTSQPWNLRCNRDARRY | Published statement 2 publications Evidence & references
| No verified residues in this structure |
| Alternative sequenceVSP_053805 | 1372–1473 | in isoform 5 | Published statement 2 publications Evidence & references
| No verified residues in this structure |
Sequence conflicts & cautions 3
Scroll across the table for evidence and actions.
3 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Sequence conflict | 287 | in Ref. 7; AAH51787 P → S | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 782 | in Ref. 1; AAG15254 T → S | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 995 | in Ref. 1; AAG15254 T → I | Curator inference Evidence & references
| No verified residues in this structure |
Source sequence: BAA76770.2
Extended N-terminus.
Evidence & references
- ECO:0000305
Source sequence: BAB15469.1
Probable cloning artifact.
Evidence & references
- ECO:0000305
Source sequence: BAB15470.1
Probable cloning artifact.
Evidence & references
- ECO:0000305
Recorded secondary structure 112
Scroll across the table for evidence and actions.
112 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Helix | 9–15 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 18–31 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 50–60 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 63–77 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 80–85 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 88–91 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 286–288 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 300–306 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 314–316 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 322–324 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 328–333 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 340–342 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 343–353 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 358–360 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 362–366 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 369–374 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 380–387 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 389–391 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 395–399 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 402–404 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 405–408 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 412–415 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 422–425 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 436–444 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 447–451 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 453–457 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 459–461 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 464–466 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 474–478 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 483–491 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 497–509 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 511–516 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 520–535 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 547–558 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 559–561 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 566–580 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 588–593 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 598–607 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 609–611 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 614–617 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 619–622 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 624–639 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 656–659 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 660–662 | Turn | Evidence & references
| No verified residues in this structure |
| Turn | 665–667 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 669–676 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 682–689 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 698–701 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 703–709 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 716–723 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 728–733 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 748–759 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 760–763 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 766–770 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 783–787 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 796–804 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 807–809 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 812–814 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 822–833 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 840–843 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 851–862 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 869–871 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 878–889 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 898–900 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 908–910 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 911–920 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 926–928 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 931–933 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 935–946 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 955–957 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 961–963 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 965–977 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 982–984 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 986–988 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1089–1092 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 1093–1096 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 1097–1102 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1104–1106 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 1111–1113 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 1116–1118 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1123–1129 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1132–1138 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 1142–1144 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 1145–1147 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1152–1156 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1163–1166 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1174–1176 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1179–1181 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1184–1188 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1191–1195 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1198–1200 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1218–1220 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1223–1225 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1234–1236 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1241–1253 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1257–1269 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 1289–1294 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1305–1308 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1314–1316 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1320–1327 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1333–1338 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 1339–1341 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 1344–1349 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1381–1384 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 1386–1392 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 1396–1403 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 1405–1407 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 1410–1417 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 1419–1421 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1422–1433 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 1438–1451 | Helix | Evidence & references
| No verified residues in this structure |
| Helix | 1453–1462 | Helix | Evidence & references
| No verified residues in this structure |
Homologs
OMA orthologs
Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.
Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.
Sources & References
Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.
Source dates & provenance
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:42:38.337898+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:42:40.478144+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:42:41.681269+00:00
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:42:38.337898+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:42:40.478144+00:00
- AlphaFold DB / DeepMind Technologies Limited / EMBL-EBI ↗ · 2026-11-09T11:42:41.681269+00:00
- UniProt overview ↗ · 2026-11-10T20:42:50.038792+00:00
- omabrowser.org ↗ · 2026-11-10T21:12:19.450826+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:19.642369+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:20.241773+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:20.298459+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:20.359705+00:00
- omabrowser.org ↗ · 2026-11-10T21:12:20.493511+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:21.090152+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:21.209043+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:21.249971+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:21.740747+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:25.301946+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:25.303095+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:26.292563+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:26.332838+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:27.350756+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:27.386270+00:00
Recorded 2026-11-10. Source dates and identifiers are retained below.
Publications in this UniProt entry
2000 · Cell Death Differ.
PubMed 11270363 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); VARIANTS HIS-155; SER-246; MET-878; VAL-1119; VAL-1184; LEU-1241 AND CYS-1366
Bertin J., DiStefano P.S.
2001 · Curr. Biol.
PubMed 11250163 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)
Martinon F., Hofmann K., Tschopp J.
2001 · J. Biol. Chem.
PubMed 11076957 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2); MUTAGENESIS OF LYS-340
Hlaing T., Guo R.-F., Dilley K.A., Loussia J.M., Morrish T.A., Shi M.M., Vincenz C., Ward P.A.
2001 · J. Biol. Chem.
PubMed 11113115 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4); FUNCTION; TISSUE SPECIFICITY; DEVELOPMENTAL STAGE
Chu Z.-L., Pio F., Xie Z., Welsh K., Krajewska M., Krajewski S., Godzik A., Reed J.C.
All source publications (50)
1999 · DNA Res.
PubMed 10231032 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)
Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.
2006 · Nature
PubMed 16625196 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.
2004 · Genome Res.
PubMed 15489334 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5)
2007 · BMC Genomics
PubMed 17974005 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 282-1473 (ISOFORM 1); VARIANT VAL-1184
Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., Wiemann S., Schupp I.
2004 · Nat. Genet.
PubMed 14702039 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 508-1473
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.
2012 · J. Biol. Chem.
PubMed 22665479 ↗Scope & authors
PROTEIN SEQUENCE OF 1213-1224; FUNCTION; INTERACTION WITH PYCARD; INVOLVEMENT IN INFLAMMASOME COMPLEX; AUTOCATALYTIC CLEAVAGE; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS VAL-1119 AND VAL-1184; MUTAGENESIS OF HIS-1168; HIS-1186; SER-1211; PHE-1212; SER-1213; PRO-1214 AND HIS-1249
Finger J.N., Lich J.D., Dare L.C., Cook M.N., Brown K.K., Duraiswami C., Bertin J.J., Bertin J., Gough P.J.
2012 · J. Biol. Chem.
Scope & authors
ERRATUM OF PUBMED:22665479
Finger J.N., Lich J.D., Dare L.C., Cook M.N., Brown K.K., Duraiswami C., Bertin J.J., Bertin J., Gough P.J.
2002 · Mol. Cell
PubMed 12191486 ↗Scope & authors
FUNCTION; INTERACTION WITH CASP1; CASP5 AND PYCARD; AUTOINHIBITION; IDENTIFICATION IN INFLAMMASOME COMPLEX
Martinon F., Burns K., Tschopp J.
2004 · Biochem. J.
PubMed 15285719 ↗Scope & authors
TISSUE SPECIFICITY; DEVELOPMENTAL STAGE
Sanz C., Calasanz M.J., Andreu E., Richard C., Prosper F., Fernandez-Luna J.L.
2004 · Cell. Signal.
PubMed 15212762 ↗Scope & authors
FUNCTION; MUTAGENESIS OF 339-GLY-LYS-340
Liu F., Lo C.F., Ning X., Kajkowski E.M., Jin M., Chiriac C., Gonzales C., Naureckiene S., Lock Y.-W., Pong K., Zaleska M.M., Jacobsen J.S., Silverman S., Ozenberger B.A.
2007 · Cell
PubMed 17418785 ↗Scope & authors
FUNCTION; INTERACTION WITH BCL2; BCL2L1; CASP5 AND PYCARD; SUBCELLULAR LOCATION; ACTIVATION BY MDP
Bruey J.M., Bruey-Sedano N., Luciano F., Zhai D., Balpai R., Xu C., Kress C.L., Bailly-Maitre B., Li X., Osterman A., Matsuzawa S., Terskikh A.V., Faustin B., Reed J.C.
2007 · Cell Death Differ.
PubMed 17431422 ↗Scope & authors
INTERACTION WITH MEFV
Papin S., Cuenin S., Agostini L., Martinon F., Werner S., Beer H.D., Grutter C., Grutter M., Tschopp J.
2007 · J. Histochem. Cytochem.
PubMed 17164409 ↗Scope & authors
SUBCELLULAR LOCATION; TISSUE SPECIFICITY; DEVELOPMENTAL STAGE
Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L., Martinon F., van Bruggen R., Tschopp J.
2007 · Mol. Cell
PubMed 17349957 ↗Scope & authors
FUNCTION; INTERACTION WITH CASP1; AUTOINHIBITION; HOMOMERIZATION; ACTIVATION BY MDP
Faustin B., Lartigue L., Bruey J.-M., Luciano F., Sergienko E., Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., Reed J.C.
2008 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 18511561 ↗Scope & authors
FUNCTION; INTERACTION WITH NOD2; ACTIVATION BY MDP
Hsu L.C., Ali S.R., McGillivray S., Tseng P.H., Mariathasan S., Humke E.W., Eckmann L., Powell J.J., Nizet V., Dixit V.M., Karin M.
2020 · Immunol. Rev.
PubMed 32558991 ↗Scope & authors
REVIEW
Taabazuing C.Y., Griswold A.R., Bachovchin D.A.
2009 · Infect. Immun.
PubMed 19651869 ↗Scope & authors
LACK OF ACTIVATION BY ANTHRAX LETHAL TOXIN; ACTIVITY REGULATION
Liao K.C., Mogridge J.
2011 · PLoS ONE
PubMed 22087307 ↗Scope & authors
FUNCTION; AUTOCATALYTIC CLEAVAGE; MUTAGENESIS OF SER-1213
D'Osualdo A., Weichenberger C.X., Wagner R.N., Godzik A., Wooley J., Reed J.C.
2012 · Nature
PubMed 22801494 ↗Scope & authors
FUNCTION; INTERACTION WITH EIF2AK2
Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.
2006 · Cell Death Differ.
PubMed 16439990 ↗Scope & authors
INTERACTION WITH VACCINIA VIRUS PROTEIN F1
Postigo A., Cross J.R., Downward J., Way M.
2014 · Int. J. Cardiol.
PubMed 24439873 ↗Scope & authors
INDUCTION
Bleda S., de Haro J., Varela C., Esparza L., Ferruelo A., Acin F.
2015 · J. Cell Biol.
PubMed 26347139 ↗Scope & authors
INTERACTION WITH MEFV
Kimura T., Jain A., Choi S.W., Mandell M.A., Schroder K., Johansen T., Deretic V.
2015 · J. Invest. Dermatol.
PubMed 25562666 ↗Scope & authors
FUNCTION
Sollberger G., Strittmatter G.E., Grossi S., Garstkiewicz M., Auf dem Keller U., French L.E., Beer H.D.
2015 · PLoS ONE
PubMed 26086088 ↗Scope & authors
INDUCTION BY ATF4
D'Osualdo A., Anania V.G., Yu K., Lill J.R., Kaufman R.J., Matsuzawa S., Reed J.C.
2018 · J. Biol. Chem.
PubMed 30291141 ↗Scope & authors
FUNCTION; ACTIVITY REGULATION; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT AIADK ARG-1214
Zhong F.L., Robinson K., Teo D.E.T., Tan K.Y., Lim C., Harapas C.R., Yu C.H., Xie W.H., Sobota R.M., Au V.B., Hopkins R., D'Osualdo A., Reed J.C., Connolly J.E., Masters S.L., Reversade B.
2018 · J. Invest. Dermatol.
PubMed 30096351 ↗Scope & authors
FUNCTION
Fenini G., Grossi S., Contassot E., Biedermann T., Reichmann E., French L.E., Beer H.D.
2019 · ACS Chem. Biol.
PubMed 31525884 ↗Scope & authors
INTERACTION WITH DPP8 AND DPP9; ACTIVITY REGULATION; MUTAGENESIS OF SER-1213
Griswold A.R., Ball D.P., Bhattacharjee A., Chui A.J., Rao S.D., Taabazuing C.Y., Bachovchin D.A.
2020 · Life Sci. Alliance
PubMed 32051255 ↗Scope & authors
FUNCTION; PROTEOLYTIC CLEAVAGE; MUTAGENESIS OF SER-1213
Ball D.P., Taabazuing C.Y., Griswold A.R., Orth E.L., Rao S.D., Kotliar I.B., Vostal L.E., Johnson D.C., Bachovchin D.A.
2020 · Science
PubMed 33243852 ↗Scope & authors
FUNCTION; ACTIVITY REGULATION; DOMAIN; MUTAGENESIS OF SER-1213; DNA-BINDING; RNA-BINDING; CATALYTIC ACTIVITY
Bauernfried S., Scherr M.J., Pichlmair A., Duderstadt K.E., Hornung V.
2021 · Cell Rep.
PubMed 33852854 ↗Scope & authors
FUNCTION
Zhou B., Abbott D.W.
2021 · Elife
PubMed 33410748 ↗Scope & authors
FUNCTION; ACTIVITY REGULATION; PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); MUTAGENESIS OF GLY-130
Tsu B.V., Beierschmitt C., Ryan A.P., Agarwal R., Mitchell P.S., Daugherty M.D.
2022 · Mol. Cell
PubMed 35594856 ↗Scope & authors
FUNCTION; ACTIVITY REGULATION (MICROBIAL INFECTION); PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); MUTAGENESIS OF GLN-333
Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.
2021 · Nature
PubMed 33731929 ↗Scope & authors
FUNCTION; ACTIVITY REGULATION; MUTAGENESIS OF PRO-1278 AND LEU-1281
Huang M., Zhang X., Toh G.A., Gong Q., Wang J., Han Z., Wu B., Zhong F., Chai J.
2022 · Nat. Immunol.
PubMed 35618833 ↗Scope & authors
SUBCELLULAR LOCATION (MICROBIAL INFECTION); INTERACTION WITH HERPES VIRUS 8/HHV-8 PROTEINS ORF45
Yang X., Zhou J., Liu C., Qu Y., Wang W., Xiao M.Z.X., Zhu F., Liu Z., Liang Q.
2022 · Science
PubMed 35857590 ↗Scope & authors
FUNCTION; PHOSPHORYLATION AT SER-93; SER-99; SER-101; SER-107; THR-112; SER-113; THR-114; THR-129; SER-132; SER-163; SER-168; SER-170; SER-173; THR-178; SER-179 AND THR-180; MUTAGENESIS OF 178-THR--THR-180
Robinson K.S., Toh G.A., Rozario P., Chua R., Bauernfried S., Sun Z., Firdaus M.J., Bayat S., Nadkarni R., Poh Z.S., Tham K.C., Harapas C.R., Lim C.K., Chu W., Tay C.W.S., Tan K.Y., Zhao T., Bonnard C., Sobota R., Connolly J.E., Common J., Masters S.L., Chen K.W., Ho L., Wu B., Hornung V., Zhong F.L.
2003 · Structure
PubMed 14527388 ↗Scope & authors
STRUCTURE BY NMR OF 1-93
Hiller S., Kohl A., Fiorito F., Herrmann T., Wider G., Tschopp J., Gruetter M.G., Wuethrich K.
OCT-2009 ·
Scope & authors
X-RAY CRYSTALLOGRAPHY
2021 · Nature
PubMed 33731932 ↗Scope & authors
STRUCTURE BY ELECTRON MICROSCOPY IN COMPLEX WITH DPP9; FUNCTION; ACTIVITY REGULATION; INTERACTION WITH DPP9; MUTAGENESIS OF 1193-LEU-LEU-1194; SER-1213; HIS-1276; LYS-1277 AND GLU-1322; CHARACTERIZATION OF VARIANT AIADK ARG-1214
Hollingsworth L.R., Sharif H., Griswold A.R., Fontana P., Mintseris J., Dagbay K.B., Paulo J.A., Gygi S.P., Bachovchin D.A., Wu H.
2021 · Nat. Commun.
PubMed 33420028 ↗Scope & authors
STRUCTURE BY ELECTRON MICROSCOPY; SUBCELLULAR LOCATION; SUBUNIT; DOMAIN; MUTAGENESIS OF ARG-1240; 1260-ARG-LYS-1261; 1278-PRO-PRO-1279; PHE-1320; ASP-1383; ARG-1386; GLU-1387; GLN-1388; ARG-1392; SER-1395; GLU-1397; LYS-1402; HIS-1404; GLN-1406; GLN-1410; GLU-1411; TYR-1413; GLU-1414; ARG-1415; ASN-1420; ARG-1422; ARG-1427; LYS-1428; GLN-1434; ASP-1437; LYS-1449; GLU-1450; THR-1451; HIS-1454; GLU-1458 AND GLU-1461
Gong Q., Robinson K., Xu C., Huynh P.T., Chong K.H.C., Tan E.Y.J., Zhang J., Boo Z.Z., Teo D.E.T., Lay K., Zhang Y., Lim J.S.Y., Goh W.I., Wright G., Zhong F.L., Reversade B., Wu B.
2021 · Nat. Commun.
PubMed 33420033 ↗Scope & authors
STRUCTURE BY ELECTRON MICROSCOPY; SUBCELLULAR LOCATION; SUBUNIT; DOMAIN; MUTAGENESIS OF ARG-1392; GLU-1397; ASP-1401; GLU-1411; GLU-1414; ARG-1427; TYR-1445; MET-1457; TRP-1460 AND GLU-1461
Robert Hollingsworth L., David L., Li Y., Griswold A.R., Ruan J., Sharif H., Fontana P., Orth-He E.L., Fu T.M., Bachovchin D.A., Wu H.
2007 · N. Engl. J. Med.
PubMed 17377159 ↗Scope & authors
INVOLVEMENT IN VAMAS1; VARIANT HIS-155
Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G., Bennett D.C., Fain P.R., Spritz R.A.
2013 · J. Med. Genet.
PubMed 23349227 ↗Scope & authors
VARIANT MSPC THR-77; TISSUE SPECIFICITY
Soler V.J., Tran-Viet K.N., Galiacy S.D., Limviphuvadh V., Klemm T.P., St Germain E., Fournie P.R., Guillaud C., Maurer-Stroh S., Hawthorne F., Suarez C., Kantelip B., Afshari N.A., Creveaux I., Luo X., Meng W., Calvas P., Cassagne M., Arne J.L., Rozen S.G., Malecaze F., Young T.L.
2016 · Cell
PubMed 27662089 ↗Scope & authors
VARIANTS MSPC THR-54; VAL-66 AND 787-PHE--ARG-843 DEL; CHARACTERIZATION OF VARIANTS MSPC THR-54; VAL-66 AND 787-PHE--ARG-843 DEL; FUNCTION; TISSUE SPECIFICITY
Zhong F.L., Mamai O., Sborgi L., Boussofara L., Hopkins R., Robinson K., Szeverenyi I., Takeichi T., Balaji R., Lau A., Tye H., Roy K., Bonnard C., Ahl P.J., Jones L.A., Baker P., Lacina L., Otsuka A., Fournie P.R., Malecaze F., Lane E.B., Akiyama M., Kabashima K., Connolly J.E., Masters S.L., Soler V.J., Omar S.S., McGrath J.A., Nedelcu R., Gribaa M., Denguezli M., Saad A., Hiller S., Reversade B.
2017 · Ann. Rheum. Dis.
PubMed 27965258 ↗Scope & authors
INVOLVEMENT IN AIADK; VARIANTS AIADK TRP-726 AND ARG-1214
Grandemange S., Sanchez E., Louis-Plence P., Tran Mau-Them F., Bessis D., Coubes C., Frouin E., Seyger M., Girard M., Puechberty J., Costes V., Rodiere M., Carbasse A., Jeziorski E., Portales P., Sarrabay G., Mondain M., Jorgensen C., Apparailly F., Hoppenreijs E., Touitou I., Genevieve D.
2019 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 31484767 ↗Scope & authors
INVOLVEMENT IN JRRP; FUNCTION; VARIANT JRRP ASN-755; CHARACTERIZATION OF VARIANT JRRP ASN-755
Drutman S.B., Haerynck F., Zhong F.L., Hum D., Hernandez N.J., Belkaya S., Rapaport F., de Jong S.J., Creytens D., Tavernier S.J., Bonte K., De Schepper S., van der Werff Ten Bosch J., Lorenzo-Diaz L., Wullaert A., Bossuyt X., Orth G., Bonagura V.R., Beziat V., Abel L., Jouanguy E., Reversade B., Casanova J.L.
2020 · Science
PubMed 33093214 ↗Scope & authors
CHARACTERIZATION OF VARIANT MSPC THR-77; FUNCTION; ACTIVITY REGULATION; PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); UBIQUITINATION; MUTAGENESIS OF GLN-76; GLN-85; GLN-87; GLN-110; GLN-130; GLN-139; GLN-158; GLN-171; GLN-191; GLN-199; GLN-205 AND PHE-1212
Robinson K.S., Teo D.E.T., Tan K.S., Toh G.A., Ong H.H., Lim C.K., Lay K., Au B.V., Lew T.S., Chu J.J.H., Chow V.T.K., Wang Y., Zhong F.L., Reversade B.
Annotation coverage audit
Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.
291 source comments and features accounted for.
View annotation inventory
| Source record | Type | Section |
|---|---|---|
| FUNCTION:0 | FUNCTION | function |
| FUNCTION:1 | FUNCTION | function |
| FUNCTION:2 | FUNCTION | function |
| FUNCTION:3 | FUNCTION | function |
| FUNCTION:4 | FUNCTION | function |
| CATALYTIC ACTIVITY:0 | CATALYTIC ACTIVITY | function |
| ACTIVITY REGULATION:0 | ACTIVITY REGULATION | function |
| ACTIVITY REGULATION:1 | ACTIVITY REGULATION | function |
| ACTIVITY REGULATION:2 | ACTIVITY REGULATION | function |
| SUBUNIT:0 | SUBUNIT | interactions |
| SUBUNIT:1 | SUBUNIT | interactions |
| SUBUNIT:2 | SUBUNIT | interactions |
| SUBUNIT:3 | SUBUNIT | interactions |
| SUBUNIT:4 | SUBUNIT | interactions |
| INTERACTION:0 | INTERACTION | interactions |
| SUBCELLULAR LOCATION:0 | SUBCELLULAR LOCATION | location |
| SUBCELLULAR LOCATION:1 | SUBCELLULAR LOCATION | location |
| SUBCELLULAR LOCATION:2 | SUBCELLULAR LOCATION | location |
| ALTERNATIVE PRODUCTS:0 | ALTERNATIVE PRODUCTS | sequence |
| TISSUE SPECIFICITY:0 | TISSUE SPECIFICITY | expression |
| DEVELOPMENTAL STAGE:0 | DEVELOPMENTAL STAGE | expression |
| INDUCTION:0 | INDUCTION | expression |
| DOMAIN:0 | DOMAIN | domains |
| DOMAIN:1 | DOMAIN | domains |
| DOMAIN:2 | DOMAIN | domains |
| DOMAIN:3 | DOMAIN | domains |
| DOMAIN:4 | DOMAIN | domains |
| DOMAIN:5 | DOMAIN | domains |
| DOMAIN:6 | DOMAIN | domains |
| PTM:0 | PTM | processing |
| PTM:1 | PTM | processing |
| PTM:2 | PTM | processing |
| PTM:3 | PTM | processing |
| PTM:4 | PTM | processing |
| DISEASE:0 | DISEASE | disease |
| DISEASE:1 | DISEASE | disease |
| DISEASE:2 | DISEASE | disease |
| DISEASE:3 | DISEASE | disease |
| MISCELLANEOUS:0 | MISCELLANEOUS | function |
| SIMILARITY:0 | SIMILARITY | domains |
| SEQUENCE CAUTION:0 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:1 | SEQUENCE CAUTION | sequence |
| SEQUENCE CAUTION:2 | SEQUENCE CAUTION | sequence |
| feature-0 | Chain | processing |
| feature-1 | Chain | processing |
| feature-2 | Chain | processing |
| feature-3 | Domain | domains |
| feature-4 | Domain | domains |
| feature-5 | Repeat | domains |
| feature-6 | Repeat | domains |
| feature-7 | Repeat | domains |
| feature-8 | Repeat | domains |
| feature-9 | Repeat | domains |
| feature-10 | Repeat | domains |
| feature-11 | Domain | domains |
| feature-12 | Domain | domains |
| feature-13 | Region | domains |
| feature-14 | Region | domains |
| feature-15 | Region | domains |
| feature-16 | Region | domains |
| feature-17 | Region | domains |
| feature-18 | Motif | domains |
| feature-19 | Motif | domains |
| feature-20 | Compositional bias | domains |
| feature-21 | Compositional bias | domains |
| feature-22 | Binding site | domains |
| feature-23 | Site | domains |
| feature-24 | Site | domains |
| feature-25 | Site | domains |
| feature-26 | Modified residue | processing |
| feature-27 | Modified residue | processing |
| feature-28 | Modified residue | processing |
| feature-29 | Modified residue | processing |
| feature-30 | Modified residue | processing |
| feature-31 | Modified residue | processing |
| feature-32 | Modified residue | processing |
| feature-33 | Modified residue | processing |
| feature-34 | Modified residue | processing |
| feature-35 | Modified residue | processing |
| feature-36 | Modified residue | processing |
| feature-37 | Modified residue | processing |
| feature-38 | Modified residue | processing |
| feature-39 | Modified residue | processing |
| feature-40 | Modified residue | processing |
| feature-41 | Modified residue | processing |
| feature-42 | Alternative sequence | sequence |
| feature-43 | Alternative sequence | sequence |
| feature-44 | Alternative sequence | sequence |
| feature-45 | Alternative sequence | sequence |
| feature-46 | Alternative sequence | sequence |
| feature-47 | Natural variant | disease |
| feature-48 | Natural variant | disease |
| feature-49 | Natural variant | disease |
| feature-50 | Natural variant | disease |
| feature-51 | Natural variant | disease |
| feature-52 | Natural variant | disease |
| feature-53 | Natural variant | disease |
| feature-54 | Natural variant | disease |
| feature-55 | Natural variant | disease |
| feature-56 | Natural variant | disease |
| feature-57 | Natural variant | disease |
| feature-58 | Natural variant | disease |
| feature-59 | Natural variant | disease |
| feature-60 | Natural variant | disease |
| feature-61 | Natural variant | disease |
| feature-62 | Natural variant | disease |
| feature-63 | Natural variant | disease |
| feature-64 | Mutagenesis | disease |
| feature-65 | Mutagenesis | disease |
| feature-66 | Mutagenesis | disease |
| feature-67 | Mutagenesis | disease |
| feature-68 | Mutagenesis | disease |
| feature-69 | Mutagenesis | disease |
| feature-70 | Mutagenesis | disease |
| feature-71 | Mutagenesis | disease |
| feature-72 | Mutagenesis | disease |
| feature-73 | Mutagenesis | disease |
| feature-74 | Mutagenesis | disease |
| feature-75 | Mutagenesis | disease |
| feature-76 | Mutagenesis | disease |
| feature-77 | Mutagenesis | disease |
| feature-78 | Mutagenesis | disease |
| feature-79 | Mutagenesis | disease |
| feature-80 | Mutagenesis | disease |
| feature-81 | Mutagenesis | disease |
| feature-82 | Mutagenesis | disease |
| feature-83 | Mutagenesis | disease |
| feature-84 | Mutagenesis | disease |
| feature-85 | Mutagenesis | disease |
| feature-86 | Mutagenesis | disease |
| feature-87 | Mutagenesis | disease |
| feature-88 | Mutagenesis | disease |
| feature-89 | Mutagenesis | disease |
| feature-90 | Mutagenesis | disease |
| feature-91 | Mutagenesis | disease |
| feature-92 | Mutagenesis | disease |
| feature-93 | Mutagenesis | disease |
| feature-94 | Mutagenesis | disease |
| feature-95 | Mutagenesis | disease |
| feature-96 | Mutagenesis | disease |
| feature-97 | Mutagenesis | disease |
| feature-98 | Mutagenesis | disease |
| feature-99 | Mutagenesis | disease |
| feature-100 | Mutagenesis | disease |
| feature-101 | Mutagenesis | disease |
| feature-102 | Mutagenesis | disease |
| feature-103 | Mutagenesis | disease |
| feature-104 | Mutagenesis | disease |
| feature-105 | Mutagenesis | disease |
| feature-106 | Mutagenesis | disease |
| feature-107 | Mutagenesis | disease |
| feature-108 | Mutagenesis | disease |
| feature-109 | Mutagenesis | disease |
| feature-110 | Mutagenesis | disease |
| feature-111 | Mutagenesis | disease |
| feature-112 | Mutagenesis | disease |
| feature-113 | Mutagenesis | disease |
| feature-114 | Mutagenesis | disease |
| feature-115 | Mutagenesis | disease |
| feature-116 | Mutagenesis | disease |
| feature-117 | Mutagenesis | disease |
| feature-118 | Mutagenesis | disease |
| feature-119 | Mutagenesis | disease |
| feature-120 | Mutagenesis | disease |
| feature-121 | Mutagenesis | disease |
| feature-122 | Mutagenesis | disease |
| feature-123 | Mutagenesis | disease |
| feature-124 | Mutagenesis | disease |
| feature-125 | Mutagenesis | disease |
| feature-126 | Mutagenesis | disease |
| feature-127 | Mutagenesis | disease |
| feature-128 | Mutagenesis | disease |
| feature-129 | Mutagenesis | disease |
| feature-130 | Mutagenesis | disease |
| feature-131 | Mutagenesis | disease |
| feature-132 | Mutagenesis | disease |
| feature-133 | Sequence conflict | sequence |
| feature-134 | Sequence conflict | sequence |
| feature-135 | Sequence conflict | sequence |
| feature-136 | Helix | sequence |
| feature-137 | Helix | sequence |
| feature-138 | Helix | sequence |
| feature-139 | Helix | sequence |
| feature-140 | Helix | sequence |
| feature-141 | Beta strand | sequence |
| feature-142 | Beta strand | sequence |
| feature-143 | Helix | sequence |
| feature-144 | Helix | sequence |
| feature-145 | Beta strand | sequence |
| feature-146 | Beta strand | sequence |
| feature-147 | Turn | sequence |
| feature-148 | Helix | sequence |
| feature-149 | Turn | sequence |
| feature-150 | Beta strand | sequence |
| feature-151 | Helix | sequence |
| feature-152 | Helix | sequence |
| feature-153 | Beta strand | sequence |
| feature-154 | Helix | sequence |
| feature-155 | Helix | sequence |
| feature-156 | Beta strand | sequence |
| feature-157 | Beta strand | sequence |
| feature-158 | Beta strand | sequence |
| feature-159 | Helix | sequence |
| feature-160 | Beta strand | sequence |
| feature-161 | Beta strand | sequence |
| feature-162 | Beta strand | sequence |
| feature-163 | Turn | sequence |
| feature-164 | Beta strand | sequence |
| feature-165 | Helix | sequence |
| feature-166 | Helix | sequence |
| feature-167 | Helix | sequence |
| feature-168 | Helix | sequence |
| feature-169 | Helix | sequence |
| feature-170 | Beta strand | sequence |
| feature-171 | Helix | sequence |
| feature-172 | Helix | sequence |
| feature-173 | Helix | sequence |
| feature-174 | Beta strand | sequence |
| feature-175 | Beta strand | sequence |
| feature-176 | Beta strand | sequence |
| feature-177 | Helix | sequence |
| feature-178 | Helix | sequence |
| feature-179 | Turn | sequence |
| feature-180 | Turn | sequence |
| feature-181 | Helix | sequence |
| feature-182 | Helix | sequence |
| feature-183 | Helix | sequence |
| feature-184 | Helix | sequence |
| feature-185 | Helix | sequence |
| feature-186 | Turn | sequence |
| feature-187 | Helix | sequence |
| feature-188 | Beta strand | sequence |
| feature-189 | Beta strand | sequence |
| feature-190 | Beta strand | sequence |
| feature-191 | Helix | sequence |
| feature-192 | Beta strand | sequence |
| feature-193 | Beta strand | sequence |
| feature-194 | Helix | sequence |
| feature-195 | Beta strand | sequence |
| feature-196 | Helix | sequence |
| feature-197 | Beta strand | sequence |
| feature-198 | Helix | sequence |
| feature-199 | Beta strand | sequence |
| feature-200 | Helix | sequence |
| feature-201 | Helix | sequence |
| feature-202 | Beta strand | sequence |
| feature-203 | Beta strand | sequence |
| feature-204 | Helix | sequence |
| feature-205 | Beta strand | sequence |
| feature-206 | Beta strand | sequence |
| feature-207 | Helix | sequence |
| feature-208 | Beta strand | sequence |
| feature-209 | Beta strand | sequence |
| feature-210 | Beta strand | sequence |
| feature-211 | Turn | sequence |
| feature-212 | Beta strand | sequence |
| feature-213 | Beta strand | sequence |
| feature-214 | Turn | sequence |
| feature-215 | Beta strand | sequence |
| feature-216 | Beta strand | sequence |
| feature-217 | Helix | sequence |
| feature-218 | Turn | sequence |
| feature-219 | Beta strand | sequence |
| feature-220 | Beta strand | sequence |
| feature-221 | Beta strand | sequence |
| feature-222 | Beta strand | sequence |
| feature-223 | Beta strand | sequence |
| feature-224 | Beta strand | sequence |
| feature-225 | Beta strand | sequence |
| feature-226 | Beta strand | sequence |
| feature-227 | Beta strand | sequence |
| feature-228 | Beta strand | sequence |
| feature-229 | Beta strand | sequence |
| feature-230 | Beta strand | sequence |
| feature-231 | Helix | sequence |
| feature-232 | Beta strand | sequence |
| feature-233 | Beta strand | sequence |
| feature-234 | Beta strand | sequence |
| feature-235 | Beta strand | sequence |
| feature-236 | Beta strand | sequence |
| feature-237 | Turn | sequence |
| feature-238 | Beta strand | sequence |
| feature-239 | Helix | sequence |
| feature-240 | Helix | sequence |
| feature-241 | Helix | sequence |
| feature-242 | Turn | sequence |
| feature-243 | Helix | sequence |
| feature-244 | Beta strand | sequence |
| feature-245 | Helix | sequence |
| feature-246 | Helix | sequence |
| feature-247 | Helix | sequence |